<doc>
  <docmeta id="113s622es">
    <bill congress="113" type="s" number="622" version="es"/>
    <revision size="91131" annotations="0" status="complete" id="6" commit-time="2013-07-11T22:25:10Z" committer="mbohmer" doc="113s622es/6.xml">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Engrossed-in-Senate" bill-type="olc" public-print="no" public-private="public" stage-count="1" star-print="no-star-print">
	<metadata>
<dublinCore>
<title>113 S622 ES: Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013</title>
<publisher>U.S. Senate</publisher>
<date/>
<format>text/xml</format>
<language>EN</language>
<rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</rights>
</dublinCore>
</metadata>
<form display="yes">
		<congress display="yes">113th CONGRESS</congress>
		<session display="yes">1st Session</session>
		<legis-num display="yes">S. 622</legis-num>
		<current-chamber display="no">IN THE SENATE OF THE UNITED
		  STATES</current-chamber>
		<legis-type display="yes">AN ACT</legis-type>
		<official-title display="yes">To amend the Federal Food, Drug, and
		  Cosmetic Act to reauthorize user fee programs relating to new animal drugs and
		  generic new animal drugs.</official-title>
	</form>
	<legis-body display-enacting-clause="yes-display-enacting-clause" style="OLC">
		<section commented="no" display-inline="no-display-inline" id="S1" section-type="section-one">
      <enum>1.</enum>
      <header display-inline="yes-display-inline">Short title</header>
      <text display-inline="no-display-inline">This Act may be cited as the
			 <quote>
          <short-title>Animal Drug and Animal Generic Drug
			 User Fee Reauthorization Act of 2013</short-title>
        </quote>.</text>
		</section>
    <section commented="no" display-inline="no-display-inline" id="id6DDE233C8DD34BA49B288F3202F70B43" section-type="subsequent-section">
      <enum>2.</enum>
      <header display-inline="yes-display-inline">Table of contents; references in
			 Act</header>
			<subsection commented="no" display-inline="no-display-inline" id="id6563FD38C07040FEB98F43E38C40CD71">
        <enum>(a)</enum>
        <header display-inline="yes-display-inline">Table of contents</header>
        <text display-inline="yes-display-inline">The table of contents of this Act is as
			 follows:</text>
				<toc>
					<toc-entry bold="off" idref="S1" level="section">Sec. 1. Short
				title.</toc-entry>
					<toc-entry bold="off" idref="id6DDE233C8DD34BA49B288F3202F70B43" level="section">Sec. 2. Table of contents; references in Act.</toc-entry>
					<toc-entry bold="off" idref="idCAB9CAD96B1741ABBCE4EB6FD7B2A456" level="title">TITLE I—Fees relating to animal drugs</toc-entry>
					<toc-entry bold="off" idref="idF24B38947FC6403FAF022C0E445C8BB9" level="section">Sec. 101. Short title; finding.</toc-entry>
					<toc-entry bold="off" idref="id18C46899033642ECAD36671387E81948" level="section">Sec. 102. Definitions.</toc-entry>
					<toc-entry bold="off" idref="idE57FA6A8996142F597DE8AD3F7810778" level="section">Sec. 103. Authority to assess and use animal drug
				fees.</toc-entry>
					<toc-entry bold="off" idref="idF95379A251544E6E81CF9BBCFDFA1C6E" level="section">Sec. 104. Reauthorization; reporting requirements.</toc-entry>
					<toc-entry bold="off" idref="idba28b0f6449e4cf594c392846a403b7d" level="section">Sec. 105. Savings clause.</toc-entry>
					<toc-entry bold="off" idref="idc9d1267aec5c4c19b7d4aa9c166e8eee" level="section">Sec. 106. Effective date.</toc-entry>
					<toc-entry bold="off" idref="id0b82b2aad4a449f1a2d259581c5c328c" level="section">Sec. 107. Sunset dates.</toc-entry>
					<toc-entry bold="off" idref="id887345CBA94A46EFAF59D050D74EF0E8" level="title">TITLE II—Fees relating to generic animal drugs</toc-entry>
					<toc-entry bold="off" idref="id7BD7ADAD8E32489AACA44A75A67EB6D3" level="section">Sec. 201. Short title; finding.</toc-entry>
					<toc-entry bold="off" idref="id105B4517DF0E45CC895D417541929E33" level="section">Sec. 202. Authority to assess and use generic new animal drug
				fees.</toc-entry>
					<toc-entry bold="off" idref="id86BF1F833AFE43B28EDEE90F35A3DA96" level="section">Sec. 203. Reauthorization; reporting requirements.</toc-entry>
					<toc-entry bold="off" idref="idE3F39FD53D1C45CCAF4D42AE9FAB3054" level="section">Sec. 204. Savings clause.</toc-entry>
					<toc-entry bold="off" idref="id0093861360504679B096AF5D36435FAA" level="section">Sec. 205. Effective date.</toc-entry>
					<toc-entry bold="off" idref="id6738992BAF6E4409B631A215FF4D8E5C" level="section">Sec. 206. Sunset dates.</toc-entry>
				</toc>
			</subsection>
      <subsection commented="no" display-inline="no-display-inline" id="idE29AD33021E4498E9F8AC1985ECF307F">
        <enum>(b)</enum>
        <header display-inline="yes-display-inline">References in Act</header>
        <text display-inline="yes-display-inline">Except as otherwise specified, amendments
			 made by this Act to a section or other provision of law are amendments to such
			 section or other provision of the <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act">Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/21/301/etseq">21
			 U.S.C. 301 et seq.</cato:entity-ref>)</cato:entity>.</text>
			</subsection>
    </section>
    <title commented="no" id="idCAB9CAD96B1741ABBCE4EB6FD7B2A456" level-type="subsequent">
      <enum>I</enum>
      <header display-inline="yes-display-inline">Fees relating to animal drugs</header>
			<section commented="no" display-inline="no-display-inline" id="idF24B38947FC6403FAF022C0E445C8BB9" section-type="subsequent-section">
        <enum>101.</enum>
        <header display-inline="yes-display-inline">Short title; finding</header>
				<subsection commented="no" display-inline="no-display-inline" id="id4D67D4B50BC5474399DBCD21987163B9">
          <enum>(a)</enum>
          <header display-inline="yes-display-inline">Short title</header>
          <text display-inline="yes-display-inline">This title may be cited as the
			 <quote>Animal Drug User Fee Amendments of 2013</quote>.</text>
				</subsection>
        <subsection commented="no" display-inline="no-display-inline" id="idCCB5BB80E2324FCCBA82464242AA3C39">
          <enum>(b)</enum>
          <header display-inline="yes-display-inline">Finding</header>
          <text display-inline="yes-display-inline">Congress finds that the fees authorized by
			 the amendments made in this title will be dedicated toward expediting the
			 animal drug development process and the review of new and supplemental animal
			 drug applications and investigational animal drug submissions as set forth in
			 the goals identified, for purposes of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/ch:VII/sch:C/pt:4">part 4 of subchapter C of chapter VII of
			 the Federal Food, Drug, and Cosmetic Act</cato:entity-ref>, in the letters from the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary of
			 Health and Human Services</cato:entity-ref> to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="HIF00">Chairman of the Committee on Energy and
			 Commerce of the House of Representatives</cato:entity-ref> and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="SSHR00">Chairman of the Committee on
			 Health, Education, Labor, and Pensions of the Senate</cato:entity-ref> as set forth in the
			 Congressional Record.</text>
				</subsection>
      </section>
      <section commented="no" display-inline="no-display-inline" id="id18C46899033642ECAD36671387E81948" section-type="subsequent-section">
        <enum>102.</enum>
        <header display-inline="yes-display-inline">Definitions</header>
        <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:739">Section 739 of the Federal Food, Drug, and
			 Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-11">21 U.S.C. 379j–11</external-xref>)</cato:entity> is amended to read as follows:</text>
				<quoted-block display-inline="no-display-inline" id="id2B676713CF5A43E7A28E98883B5193AF" style="OLC">
					<section commented="no" display-inline="no-display-inline" id="id2cfb2137b4f849b28383ff7535ad2157" section-type="subsequent-section">
            <enum>739.</enum>
            <header display-inline="yes-display-inline">Definitions</header>
            <text display-inline="no-display-inline">For purposes of this part:</text>
						<paragraph commented="no" display-inline="no-display-inline" id="id2baecaa2201646fd847452d9d7af16b4">
              <enum>(1)</enum>
              <text display-inline="yes-display-inline">The term
				<term>animal drug application</term> means an application for approval of any
				new animal drug submitted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:b/p:1">section 512(b)(1)</cato:entity-ref>. Such term does not include
				either a new animal drug application submitted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:b/p:2">section 512(b)(2)</cato:entity-ref> or a
				supplemental animal drug application.</text>
						</paragraph>
            <paragraph commented="no" display-inline="no-display-inline" id="id75dc24faa3c34c498fbfd7528f195f29">
              <enum>(2)</enum>
              <text display-inline="yes-display-inline">The term <term>supplemental animal drug
				application</term> means—</text>
							<subparagraph commented="no" display-inline="no-display-inline" id="id8d119fd21c4648d1a326ef814ae2b4b4">
                <enum>(A)</enum>
                <text display-inline="yes-display-inline">a request to the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> to approve a change in an animal drug application which has been
				approved; or</text>
							</subparagraph>
              <subparagraph commented="no" display-inline="no-display-inline" id="id51e3012b17c1410a992ed6c288462421">
                <enum>(B)</enum>
                <text display-inline="yes-display-inline">a request to the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> to approve a change to an application approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:c/p:2">section
				512(c)(2)</cato:entity-ref> for which data with respect to safety or effectiveness are
				required.</text>
							</subparagraph>
            </paragraph>
            <paragraph commented="no" display-inline="no-display-inline" id="id6a97e76f119640d7b7489daab6a5cb06">
              <enum>(3)</enum>
              <text display-inline="yes-display-inline">The term <term>animal drug product</term>
				means each specific strength or potency of a particular active ingredient or
				ingredients in final dosage form marketed by a particular manufacturer or
				distributor, which is uniquely identified by the labeler code and product code
				portions of the national drug code, and for which an animal drug application or
				a supplemental animal drug application has been approved.</text>
						</paragraph>
            <paragraph commented="no" display-inline="no-display-inline" id="id45066d48e5bb4af196d4277a5d52bba1">
              <enum>(4)</enum>
              <text display-inline="yes-display-inline">The term <term>animal drug
				establishment</term> means a foreign or domestic place of business which is at
				one general physical location consisting of one or more buildings all of which
				are within 5 miles of each other, at which one or more animal drug products are
				manufactured in final dosage form.</text>
						</paragraph>
            <paragraph commented="no" display-inline="no-display-inline" id="ide9601ceef80e4db78d44d5541181cf2b">
              <enum>(5)</enum>
              <text display-inline="yes-display-inline">The term <term>investigational animal drug
				submission</term> means—</text>
							<subparagraph commented="no" display-inline="no-display-inline" id="id2edccab7936b46849d1ecbf6ec00a0d1">
                <enum>(A)</enum>
                <text display-inline="yes-display-inline">the filing of a
				claim for an investigational exemption under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:j">section 512(j)</cato:entity-ref> for a new animal
				drug intended to be the subject of an animal drug application or a supplemental
				animal drug application; or</text>
							</subparagraph>
              <subparagraph commented="no" display-inline="no-display-inline" id="id2752196ae8cb42f28d7d3fb12d4b4533">
                <enum>(B)</enum>
                <text display-inline="yes-display-inline">the submission of
				information for the purpose of enabling the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> to evaluate the safety or
				effectiveness of an animal drug application or supplemental animal drug
				application in the event of their filing.</text>
							</subparagraph>
            </paragraph>
            <paragraph commented="no" display-inline="no-display-inline" id="idab5aa508c9ec4de8ac04cf107a60fd1b">
              <enum>(6)</enum>
              <text display-inline="yes-display-inline">The term
				<term>animal drug sponsor</term> means either an applicant named in an animal
				drug application that has not been withdrawn by the applicant and for which
				approval has not been withdrawn by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, or a person who has submitted
				an investigational animal drug submission that has not been terminated or
				otherwise rendered inactive by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>.</text>
						</paragraph>
            <paragraph commented="no" display-inline="no-display-inline" id="id59ce977dfbc243cab1f36852f9980932">
              <enum>(7)</enum>
              <text display-inline="yes-display-inline">The term <term>final dosage form</term>
				means, with respect to an animal drug product, a finished dosage form which is
				approved for administration to an animal without substantial further
				manufacturing. Such term includes animal drug products intended for mixing in
				animal feeds.</text>
						</paragraph>
            <paragraph commented="no" display-inline="no-display-inline" id="id8d7966ae48ef4a6fb99cb5bdb30638fd">
              <enum>(8)</enum>
              <text display-inline="yes-display-inline">The term
				<term>process for the review of animal drug applications</term> means the
				following activities of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> with respect to the review of animal drug
				applications, supplemental animal drug applications, and investigational animal
				drug submissions:</text>
							<subparagraph commented="no" display-inline="no-display-inline" id="id57760b3930c54f8b9873957f96fb72cb">
                <enum>(A)</enum>
                <text display-inline="yes-display-inline">The activities necessary for the review of
				animal drug applications, supplemental animal drug applications, and
				investigational animal drug submissions.</text>
							</subparagraph>
              <subparagraph commented="no" display-inline="no-display-inline" id="id0e6dbab31cf54fd2a5ed64fd3059f60b">
                <enum>(B)</enum>
                <text display-inline="yes-display-inline">The issuance of action letters which
				approve animal drug applications or supplemental animal drug applications or
				which set forth in detail the specific deficiencies in animal drug
				applications, supplemental animal drug applications, or investigational animal
				drug submissions and, where appropriate, the actions necessary to place such
				applications, supplements or submissions in condition for approval.</text>
							</subparagraph>
              <subparagraph commented="no" display-inline="no-display-inline" id="ida5ed9b515c064d799b9b1dd5bd635681">
                <enum>(C)</enum>
                <text display-inline="yes-display-inline">The inspection of
				animal drug establishments and other facilities undertaken as part of the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary’s</cato:entity-ref> review of pending animal drug applications, supplemental animal
				drug applications, and investigational animal drug submissions.</text>
							</subparagraph>
              <subparagraph commented="no" display-inline="no-display-inline" id="id4660e2af831f46c6b5219d1b9b5088a3">
                <enum>(D)</enum>
                <text display-inline="yes-display-inline">Monitoring of research conducted in
				connection with the review of animal drug applications, supplemental animal
				drug applications, and investigational animal drug submissions.</text>
							</subparagraph>
              <subparagraph commented="no" display-inline="no-display-inline" id="id16c5e7d415c240c39e1a7764e7c8aa43">
                <enum>(E)</enum>
                <text display-inline="yes-display-inline">The development of regulations and policy
				related to the review of animal drug applications, supplemental animal drug
				applications, and investigational animal drug submissions.</text>
							</subparagraph>
              <subparagraph commented="no" display-inline="no-display-inline" id="idbca0bdd8d87d4c42987b6660266a124a">
                <enum>(F)</enum>
                <text display-inline="yes-display-inline">Development of standards for products
				subject to review.</text>
							</subparagraph>
              <subparagraph commented="no" display-inline="no-display-inline" id="idd31eb8de324c4ed98b7d171b426aa0d6">
                <enum>(G)</enum>
                <text display-inline="yes-display-inline">Meetings between the agency and the animal
				drug sponsor.</text>
							</subparagraph>
              <subparagraph commented="no" display-inline="no-display-inline" id="id9ec33da95791400882f4a37b4d293a0d">
                <enum>(H)</enum>
                <text display-inline="yes-display-inline">Review of advertising and labeling prior to
				approval of an animal drug application or supplemental animal drug application,
				but not after such application has been approved.</text>
							</subparagraph>
            </paragraph>
            <paragraph commented="no" display-inline="no-display-inline" id="id280ae9c17847498cb26aebb44e12376e">
              <enum>(9)</enum>
              <text display-inline="yes-display-inline">The term <term>costs of resources allocated
				for the process for the review of animal drug applications</term> means the
				expenses in connection with the process for the review of animal drug
				applications for—</text>
							<subparagraph commented="no" display-inline="no-display-inline" id="id4a075b710b6a4c508c6b1e88e547b378">
                <enum>(A)</enum>
                <text display-inline="yes-display-inline">officers and
				employees of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref>, contractors of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug
				Administration</cato:entity-ref>, advisory committees consulted with respect to the review of
				specific animal drug applications, supplemental animal drug applications, or
				investigational animal drug submissions, and costs related to such officers,
				employees, committees, and contractors, including costs for travel, education,
				and recruitment and other personnel activities;</text>
							</subparagraph>
              <subparagraph commented="no" display-inline="no-display-inline" id="idb8bac221e506493fa513ba7b1b6488cc">
                <enum>(B)</enum>
                <text display-inline="yes-display-inline">management of information and the
				acquisition, maintenance, and repair of computer resources;</text>
							</subparagraph>
              <subparagraph commented="no" display-inline="no-display-inline" id="id0f945ec9caf748b3a1398c0ece5557e3">
                <enum>(C)</enum>
                <text display-inline="yes-display-inline">leasing, maintenance, renovation, and
				repair of facilities and acquisition, maintenance, and repair of fixtures,
				furniture, scientific equipment, and other necessary materials and supplies;
				and</text>
							</subparagraph>
              <subparagraph commented="no" display-inline="no-display-inline" id="id33d0d930d7814ff1ab1fa64b560de746">
                <enum>(D)</enum>
                <text display-inline="yes-display-inline">collecting fees
				under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740">section 740</cato:entity-ref> and accounting for resources allocated for the review of
				animal drug applications, supplemental animal drug applications, and
				investigational animal drug submissions.</text>
							</subparagraph>
            </paragraph>
            <paragraph commented="no" display-inline="no-display-inline" id="idda64e305fd5e4f5ba8c1921029ec65db">
              <enum>(10)</enum>
              <text display-inline="yes-display-inline">The term
				<term>adjustment factor</term> applicable to a fiscal year refers to the
				formula set forth in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:735/p:8">section 735(8)</cato:entity-ref> with the base or comparator month being
				October 2002.</text>
						</paragraph>
            <paragraph commented="no" display-inline="no-display-inline" id="idd530b8631d82409d9e199b02bf4b90b9">
              <enum>(11)</enum>
              <text display-inline="yes-display-inline">The term <term>person</term> includes an
				affiliate thereof.</text>
						</paragraph>
            <paragraph commented="no" display-inline="no-display-inline" id="ida520e53d480c419d99108ffc83029fe8">
              <enum>(12)</enum>
              <text display-inline="yes-display-inline">The term
				<term>affiliate</term> refers to the definition set forth in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:735/p:11">section
				735(11)</cato:entity-ref>.</text>
						</paragraph>
          </section>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</section>
      <section commented="no" display-inline="no-display-inline" id="idE57FA6A8996142F597DE8AD3F7810778" section-type="subsequent-section">
        <enum>103.</enum>
        <header display-inline="yes-display-inline">Authority to assess and use animal drug
			 fees</header>
        <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740">Section 740 of the Federal Food, Drug, and
			 Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-12">21 U.S.C. 379j–12</external-xref>)</cato:entity> is amended to read as follows:</text>
				<quoted-block display-inline="no-display-inline" id="idE6F90BE0E0A74214B31A51B5B1004BEC" style="OLC">
					<section commented="no" display-inline="no-display-inline" id="id20bd7243cd6d4ec0bde67d3531977f61" section-type="subsequent-section">
            <enum>740.</enum>
            <header display-inline="yes-display-inline">Authority to assess and use animal drug
				fees</header>
						<subsection commented="no" display-inline="no-display-inline" id="id2dc2344c349f4586842f585b9e903b2a">
              <enum>(a)</enum>
              <header display-inline="yes-display-inline">Types of fees</header>
              <text display-inline="yes-display-inline">Beginning in fiscal year 2004, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall assess
				and collect fees in accordance with this section as follows:</text>
							<paragraph commented="no" display-inline="no-display-inline" id="id856c6a5f331349858672440b4b1afaef">
                <enum>(1)</enum>
                <header display-inline="yes-display-inline">Animal drug application and supplement
				fee</header>
								<subparagraph commented="no" display-inline="no-display-inline" id="id96eff9f07a5842a4a4b1a8d0e987e7f7">
                  <enum>(A)</enum>
                  <header display-inline="yes-display-inline">In general</header>
                  <text display-inline="yes-display-inline">Each person that submits, on or after
				September 1, 2003, an animal drug application or a supplemental animal drug
				application shall be subject to a fee as follows:</text>
									<clause commented="no" display-inline="no-display-inline" id="idf3be932ff6c44f0eb559e8781c278625">
                    <enum>(i)</enum>
                    <text display-inline="yes-display-inline">A fee established in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:c" proposed="true">subsection (c)</cato:entity-ref> for an
				animal drug application, except an animal drug application subject to the
				criteria set forth in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:d/p:4">section 512(d)(4)</cato:entity-ref>.</text>
									</clause>
                  <clause commented="no" display-inline="no-display-inline" id="id0ea29b3247bb47aebd6f6599a5adb1f7">
                    <enum>(ii)</enum>
                    <text display-inline="yes-display-inline">A
				fee established in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:c" proposed="true">subsection (c)</cato:entity-ref>, in an amount that is equal to 50 percent of
				the amount of the fee under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a/p:1/sp:A/cl:i" proposed="true">clause (i)</cato:entity-ref>, for—</text>
										<subclause commented="no" display-inline="no-display-inline" id="id71eba9cd8cc9432bb086eae9b19271f1">
                      <enum>(I)</enum>
                      <text display-inline="yes-display-inline">a supplemental animal drug application for
				which safety or effectiveness data are required; and</text>
										</subclause>
                    <subclause commented="no" display-inline="no-display-inline" id="iddaa6e8cc556745eba9d35e6e6cfdf566">
                      <enum>(II)</enum>
                      <text display-inline="yes-display-inline">an animal drug application subject to the
				criteria set forth in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:d/p:4">section 512(d)(4)</cato:entity-ref>.</text>
										</subclause>
                  </clause>
                </subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="idad0ccb7a9ce2485e856a3962aa83a00b">
                  <enum>(B)</enum>
                  <header display-inline="yes-display-inline">Payment</header>
                  <text display-inline="yes-display-inline">The
				fee required by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a/p:1/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> shall be due upon submission of the animal
				drug application or supplemental animal drug application.</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id00381df24dbb4c6fa9672051607e83ff">
                  <enum>(C)</enum>
                  <header display-inline="yes-display-inline">Exception for previously filed application
				or supplement</header>
                  <text display-inline="yes-display-inline">If an animal drug
				application or a supplemental animal drug application was submitted by a person
				that paid the fee for such application or supplement, was accepted for filing,
				and was not approved or was withdrawn (without a waiver or refund), the
				submission of an animal drug application or a supplemental animal drug
				application for the same product by the same person (or the person’s licensee,
				assignee, or successor) shall not be subject to a fee under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a/p:1/sp:A" proposed="true">subparagraph
				(A)</cato:entity-ref>.</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id1fb0e71de8754f73b85f71fbdeec1d3a">
                  <enum>(D)</enum>
                  <header display-inline="yes-display-inline">Refund of fee if application refused for
				filing</header>
                  <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall refund 75
				percent of the fee paid under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a/p:1/sp:B" proposed="true">subparagraph (B)</cato:entity-ref> for any animal drug application
				or supplemental animal drug application which is refused for filing.</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="ida24a0748809b462995e81936d8d6a70c">
                  <enum>(E)</enum>
                  <header display-inline="yes-display-inline">Refund of fee if application
				withdrawn</header>
                  <text display-inline="yes-display-inline">If an animal drug application or a
				supplemental animal drug application is withdrawn after the application or
				supplement was filed, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may refund the fee or portion of the fee
				paid under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a/p:1/sp:B" proposed="true">subparagraph (B)</cato:entity-ref> if no substantial work was performed on the
				application or supplement after the application or supplement was filed. The
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall have the sole discretion to refund the fee under this
				paragraph. A determination by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> concerning a refund under this
				paragraph shall not be reviewable.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="idd244aeb1ac2344d6963dbdab2111e2ec">
                <enum>(2)</enum>
                <header display-inline="yes-display-inline">Animal drug product fee</header>
								<subparagraph commented="no" display-inline="no-display-inline" id="ida938326684b7416ab2de970e84282893">
                  <enum>(A)</enum>
                  <header display-inline="yes-display-inline">In general</header>
                  <text display-inline="yes-display-inline">Each person—</text>
									<clause commented="no" display-inline="no-display-inline" id="idBC3298020FB0493AA055F3DCBFD9368F">
                    <enum>(i)</enum>
                    <text display-inline="yes-display-inline">who is named as the applicant in an animal
				drug application or supplemental animal drug application for an animal drug
				product which has been submitted for listing under section 510; and</text>
									</clause>
                  <clause commented="no" display-inline="no-display-inline" id="id05148E5A0284418DA64B1C1692C81E56">
                    <enum>(ii)</enum>
                    <text display-inline="yes-display-inline">who, after September 1, 2003, had pending
				before the Secretary an animal drug application or supplemental animal drug
				application,</text>
									</clause>
                  <continuation-text commented="no" continuation-text-level="subparagraph">shall pay for each such animal
				drug product the annual fee established in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:c" proposed="true">subsection (c)</cato:entity-ref>.</continuation-text>
                </subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id286d4e36fdf44cd9bc435819a7fbd697">
                  <enum>(B)</enum>
                  <header display-inline="yes-display-inline">Payment; fee due date</header>
                  <text display-inline="yes-display-inline">Such fee shall be payable for the fiscal year in which the
				animal drug product is first submitted for listing under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510">section 510</cato:entity-ref>, or is
				submitted for relisting under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510">section 510</cato:entity-ref> if the animal drug product has been
				withdrawn from listing and relisted. After such fee is paid for that fiscal
				year, such fee shall be due each subsequent fiscal year that the product
				remains listed, upon the later of—</text>
									<clause commented="no" display-inline="no-display-inline" id="id2a6ea392d4da47048129573d63242b2b">
                    <enum>(i)</enum>
                    <text display-inline="yes-display-inline">the first business day after the date of
				enactment of an appropriations Act providing for the collection and obligation
				of fees for such fiscal year under this section; or</text>
									</clause>
                  <clause commented="no" display-inline="no-display-inline" id="idb2ec0ea5d79140838a1d2f511c1e3dc7">
                    <enum>(ii)</enum>
                    <text display-inline="yes-display-inline">January 31 of each year.</text>
									</clause>
                </subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id2c4425400aea4a6b88a4e752b3c37385">
                  <enum>(C)</enum>
                  <header display-inline="yes-display-inline">Limitation</header>
                  <text display-inline="yes-display-inline">Such fee shall be paid only once for each
				animal drug product for a fiscal year in which the fee is payable.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="idec70ef13a7d74d6ba337a08e294490a4">
                <enum>(3)</enum>
                <header display-inline="yes-display-inline">Animal drug establishment fee</header>
								<subparagraph commented="no" display-inline="no-display-inline" id="id010c49a9657a4137bd22196c97c59427">
                  <enum>(A)</enum>
                  <header display-inline="yes-display-inline">In general</header>
                  <text display-inline="yes-display-inline">Each person—</text>
									<clause commented="no" display-inline="no-display-inline" id="id4acd4cf9864a448a847fa0d313f4f3a3">
                    <enum>(i)</enum>
                    <text display-inline="yes-display-inline">who owns or operates, directly or through
				an affiliate, an animal drug establishment;</text>
									</clause>
                  <clause commented="no" display-inline="no-display-inline" id="id642d0b026cdc4f2bbe966b32014f852e">
                    <enum>(ii)</enum>
                    <text display-inline="yes-display-inline">who is named as the applicant in an animal
				drug application or supplemental animal drug application for an animal drug
				product which has been submitted for listing under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510">section 510</cato:entity-ref>; and</text>
									</clause>
                  <clause commented="no" display-inline="no-display-inline" id="id9c7fb6e0216b4ece94ac63dfe6413f60">
                    <enum>(iii)</enum>
                    <text display-inline="yes-display-inline">who, after September 1, 2003, had pending
				before the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> an animal drug application or supplemental animal drug
				application,</text>
									</clause>
                  <continuation-text commented="no" continuation-text-level="subparagraph">shall be assessed an annual
				establishment fee as established in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:c" proposed="true">subsection (c)</cato:entity-ref> for each animal drug
				establishment listed in its approved animal drug application as an
				establishment that manufactures the animal drug product named in the
				application.</continuation-text>
                </subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id3f9baeb57de64faf8d8657f94716b49e">
                  <enum>(B)</enum>
                  <header display-inline="yes-display-inline">Payment; fee due date</header>
                  <text display-inline="yes-display-inline">The annual establishment fee shall be assessed in each
				fiscal year in which the animal drug product named in the application is
				assessed a fee under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a/p:2" proposed="true">paragraph (2)</cato:entity-ref> unless the animal drug establishment listed
				in the application does not engage in the manufacture of the animal drug
				product during the fiscal year. The fee under this paragraph for a fiscal year
				shall be due upon the later of—</text>
									<clause commented="no" display-inline="no-display-inline" id="id6c8e2638580f4fecab2326fb11e275e1">
                    <enum>(i)</enum>
                    <text display-inline="yes-display-inline">the first business day after the date of
				enactment of an appropriations Act providing for the collection and obligation
				of fees for such fiscal year under this section; or</text>
									</clause>
                  <clause commented="no" display-inline="no-display-inline" id="id8288061bb7b24630b96cd9f96dad6f2e">
                    <enum>(ii)</enum>
                    <text display-inline="yes-display-inline">January 31 of each year.</text>
									</clause>
                </subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id1ca0cb6f97034855983c73b83030b397">
                  <enum>(C)</enum>
                  <header display-inline="yes-display-inline">Limitation</header>
									<clause commented="no" display-inline="no-display-inline" id="id85654F3F1AD54EE7BCE665138E7EBF7A">
                    <enum>(i)</enum>
                    <header display-inline="yes-display-inline">In general</header>
                    <text display-inline="yes-display-inline">An establishment shall be assessed only one fee per
				fiscal year under this section, subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a/p:3/sp:C/cl:ii" proposed="true">clause (ii)</cato:entity-ref>.</text>
									</clause>
                  <clause commented="no" display-inline="no-display-inline" id="id4C9A24E9FF104B879A9F8E585E05E10A">
                    <enum>(ii)</enum>
                    <header display-inline="yes-display-inline">Certain manufacturers</header>
                    <text display-inline="yes-display-inline">If a single establishment manufactures both animal
				drug products and prescription drug products, as defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:735/p:3">section 735(3)</cato:entity-ref>,
				such establishment shall be assessed both the animal drug establishment fee and
				the prescription drug establishment fee, as set forth in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:736/ss:a/p:2">section 736(a)(2)</cato:entity-ref>,
				within a single fiscal year.</text>
									</clause>
                </subparagraph>
              </paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="id5e99b2cdcba34a879d151c9d44a84bb1">
                <enum>(4)</enum>
                <header display-inline="yes-display-inline">Animal drug sponsor fee</header>
								<subparagraph commented="no" display-inline="no-display-inline" id="idc86ef39ce2f34dd3a7ce643d12eba1a6">
                  <enum>(A)</enum>
                  <header display-inline="yes-display-inline">In general</header>
                  <text display-inline="yes-display-inline">Each person—</text>
									<clause commented="no" display-inline="no-display-inline" id="id4713777554EA4736B68AE28C4A83A989">
                    <enum>(i)</enum>
                    <text display-inline="yes-display-inline">who meets the definition of an animal drug
				sponsor within a fiscal year; and</text>
									</clause>
                  <clause commented="no" display-inline="no-display-inline" id="id75DDE84866DB44BCA26229F56E7666E2">
                    <enum>(ii)</enum>
                    <text display-inline="yes-display-inline">who, after
				September 1, 2003, had pending before the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> an animal drug application,
				a supplemental animal drug application, or an investigational animal drug
				submission,</text>
									</clause>
                  <continuation-text commented="no" continuation-text-level="subparagraph">shall be assessed an annual
				sponsor fee as established under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:c" proposed="true">subsection (c)</cato:entity-ref>.</continuation-text>
                </subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id9bbd59ab18014db9917df43009811793">
                  <enum>(B)</enum>
                  <header display-inline="yes-display-inline">Payment; fee due date</header>
                  <text display-inline="yes-display-inline">The fee under this paragraph for a fiscal
				year shall be due upon the later of—</text>
									<clause commented="no" display-inline="no-display-inline" id="id7e4068f8a77841669b9f09685ef74e6e">
                    <enum>(i)</enum>
                    <text display-inline="yes-display-inline">the first business day after the date of
				enactment of an appropriations Act providing for the collection and obligation
				of fees for such fiscal year under this section; or</text>
									</clause>
                  <clause commented="no" display-inline="no-display-inline" id="iddb992fd0b12f410fb9360a188d36568c">
                    <enum>(ii)</enum>
                    <text display-inline="yes-display-inline">January 31 of each year.</text>
									</clause>
                </subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="idf247453a92744a588729e8746796c011">
                  <enum>(C)</enum>
                  <header display-inline="yes-display-inline">Limitation</header>
                  <text display-inline="yes-display-inline">Each animal drug sponsor shall pay only one
				such fee each fiscal year.</text>
								</subparagraph>
              </paragraph>
            </subsection>
            <subsection commented="no" display-inline="no-display-inline" id="idaf35bbefbdb747f09941f1977c0d1bdc">
              <enum>(b)</enum>
              <header display-inline="yes-display-inline">Fee revenue amounts</header>
							<paragraph commented="no" display-inline="no-display-inline" id="idc6f6d9a0f4fb4101bf6de214b0d82488">
                <enum>(1)</enum>
                <header display-inline="yes-display-inline">In general</header>
                <text display-inline="yes-display-inline">Subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:c" proposed="true">subsections (c)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:d" proposed="true">(d)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:f" proposed="true">(f)</cato:entity-ref>, and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:g" proposed="true">(g)</cato:entity-ref>—</text>
								<subparagraph commented="no" display-inline="no-display-inline" id="id6a536a7f69564371933dc08c908acabf">
                  <enum>(A)</enum>
                  <text display-inline="yes-display-inline">for fiscal year
				2014, the fees required under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a" proposed="true">subsection (a)</cato:entity-ref> shall be established to generate a
				total revenue amount of $23,600,000; and</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="idb13cfed06f6e4e7aa99336a2bf060685">
                  <enum>(B)</enum>
                  <text display-inline="yes-display-inline">for each of fiscal
				years 2015 through 2018, the fees required under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a" proposed="true">subsection (a)</cato:entity-ref> shall be
				established to generate a total revenue amount of $21,600,000.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="idee0a35c16b3a4f43ad07525becf7368b">
                <enum>(2)</enum>
                <header display-inline="yes-display-inline">Types of fees</header>
                <text display-inline="yes-display-inline">Of the total revenue amount determined for a fiscal year
				under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:b/p:1" proposed="true">paragraph (1)</cato:entity-ref>—</text>
								<subparagraph commented="no" display-inline="no-display-inline" id="idcba4797710da4bcf9dac068921f3f593">
                  <enum>(A)</enum>
                  <text display-inline="yes-display-inline">20 percent shall
				be derived from fees under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a/p:1" proposed="true">subsection (a)(1)</cato:entity-ref> (relating to animal drug
				applications and supplements);</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="ide8c86e8cc8f744a99e582ad1290ed7eb">
                  <enum>(B)</enum>
                  <text display-inline="yes-display-inline">27 percent shall
				be derived from fees under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a/p:2" proposed="true">subsection (a)(2)</cato:entity-ref> (relating to animal drug
				products);</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id85513e950b0c458eb546e8af614947ef">
                  <enum>(C)</enum>
                  <text display-inline="yes-display-inline">26 percent shall
				be derived from fees under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a/p:3" proposed="true">subsection (a)(3)</cato:entity-ref> (relating to animal drug
				establishments); and</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id3cd66be54caf46099e22401bebd73de5">
                  <enum>(D)</enum>
                  <text display-inline="yes-display-inline">27 percent shall
				be derived from fees under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a/p:4" proposed="true">subsection (a)(4)</cato:entity-ref> (relating to animal drug
				sponsors).</text>
								</subparagraph>
              </paragraph>
            </subsection>
            <subsection commented="no" display-inline="no-display-inline" id="id1a1c4f8297ca4fa5adf7d7ad041d4c12">
              <enum>(c)</enum>
              <header display-inline="yes-display-inline">Annual fee setting; adjustments</header>
							<paragraph commented="no" display-inline="no-display-inline" id="id1be44308ec41422c91c09183f6d5a32f">
                <enum>(1)</enum>
                <header display-inline="yes-display-inline">Annual fee setting</header>
                <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall establish, 60 days before the start
				of each fiscal year beginning after September 30, 2003, for that fiscal year,
				animal drug application fees, supplemental animal drug application fees, animal
				drug sponsor fees, animal drug establishment fees, and animal drug product fees
				based on the revenue amounts established under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:b" proposed="true">subsection (b)</cato:entity-ref> and the
				adjustments provided under this subsection.</text>
							</paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="idab2a98ea0a174a14b3c19e52ec354a1f">
                <enum>(2)</enum>
                <header display-inline="yes-display-inline">Inflation adjustment</header>
                <text display-inline="yes-display-inline">For fiscal year 2015 and subsequent fiscal years, the
				revenue amounts established in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:b" proposed="true">subsection (b)</cato:entity-ref> shall be adjusted by the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> by notice, published in the Federal Register, for a fiscal year, by
				an amount equal to the sum of—</text>
								<subparagraph commented="no" display-inline="no-display-inline" id="id11ecb2d82c084e5b85946436249a2b58">
                  <enum>(A)</enum>
                  <text display-inline="yes-display-inline">one;</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id45520518539845659230174a4d7e3886">
                  <enum>(B)</enum>
                  <text display-inline="yes-display-inline">the average annual
				percent change in the cost, per full-time equivalent position of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and
				Drug Administration</cato:entity-ref>, of all personnel compensation and benefits paid with
				respect to such positions for the first 3 of the preceding 4 fiscal years for
				which data are available, multiplied by the average proportion of personnel
				compensation and benefits costs to total <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> costs for
				the first 3 years of the preceding 4 fiscal years for which data are available;
				and</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="ide1111c4d711a4bc0b60c7bdf4ef39252">
                  <enum>(C)</enum>
                  <text display-inline="yes-display-inline">the average annual percent change that
				occurred in the Consumer Price Index for urban consumers (Washington-Baltimore,
				DC–MD–VA–WV; not seasonally adjusted; all items less food and energy; annual
				index) for the first 3 years of the preceding 4 years for which data are
				available multiplied by the average proportion of all costs other than
				personnel compensation and benefits costs to total <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref>
				costs for the first 3 years of the preceding 4 fiscal years for which data are
				available.</text>
								</subparagraph>
                <continuation-text commented="no" continuation-text-level="paragraph">The adjustment made each fiscal year
				under this paragraph shall be added on a compounded basis to the sum of all
				adjustments made each fiscal year after fiscal year 2014 under this
				paragraph.</continuation-text>
              </paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="ida926d9804abd48fa97bb5eafb148e7d3">
                <enum>(3)</enum>
                <header display-inline="yes-display-inline">Workload adjustment</header>
                <text display-inline="yes-display-inline">For fiscal year 2015 and subsequent fiscal years,
				after the revenue amounts established in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:b" proposed="true">subsection (b)</cato:entity-ref> are adjusted for
				inflation in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:c/p:2" proposed="true">paragraph (2)</cato:entity-ref>, the revenue amounts shall be
				further adjusted for such fiscal year to reflect changes in the workload of the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> for the process for the review of animal drug applications. With
				respect to such adjustment—</text>
								<subparagraph commented="no" display-inline="no-display-inline" id="id8cf934fc86e7475cb281bedfcfde33c6">
                  <enum>(A)</enum>
                  <text display-inline="yes-display-inline">such adjustment
				shall be determined by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> based on a weighted average of the change
				in the total number of animal drug applications, supplemental animal drug
				applications for which data with respect to safety or effectiveness are
				required, manufacturing supplemental animal drug applications, investigational
				animal drug study submissions, and investigational animal drug protocol
				submissions submitted to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>;</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="idA23B3BFEEFD947EDB19E5DF7AE6AB4DF">
                  <enum>(B)</enum>
                  <text display-inline="yes-display-inline">the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				shall publish in the Federal Register the fees resulting from such adjustment
				and the supporting methodologies; and</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id241d33caa9aa4458a1ffefc8dde96f73">
                  <enum>(C)</enum>
                  <text display-inline="yes-display-inline">under no
				circumstances shall such adjustment result in fee revenues for a fiscal year
				that are less than the fee revenues for that fiscal year established in
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:b" proposed="true">subsection (b)</cato:entity-ref>, as adjusted for inflation under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:c/p:2" proposed="true">paragraph (2)</cato:entity-ref>.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="id22d236418f804be3a2a7dec79c87d001">
                <enum>(4)</enum>
                <header display-inline="yes-display-inline">Final year adjustment</header>
                <text display-inline="yes-display-inline">For fiscal year 2018, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may, in
				addition to other adjustments under this subsection, further increase the fees
				under this section, if such an adjustment is necessary, to provide for up to 3
				months of operating reserves of carryover user fees for the process for the
				review of animal drug applications for the first 3 months of fiscal year 2019.
				If the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> has carryover balances for the process for
				the review of animal drug applications in excess of 3 months of such operating
				reserves, then this adjustment will not be made. If this adjustment is
				necessary, then the rationale for the amount of the increase shall be contained
				in the annual notice setting fees for fiscal year 2018.</text>
							</paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="id41001dd940b1473fb08295986f21c6a6">
                <enum>(5)</enum>
                <header display-inline="yes-display-inline">Limit</header>
                <text display-inline="yes-display-inline">The total amount of fees charged, as
				adjusted under this subsection, for a fiscal year may not exceed the total
				costs for such fiscal year for the resources allocated for the process for the
				review of animal drug applications.</text>
							</paragraph>
            </subsection>
            <subsection commented="no" display-inline="no-display-inline" id="id5f5654bf3e724bb5ad446f03903c5dad">
              <enum>(d)</enum>
              <header display-inline="yes-display-inline">Fee waiver or reduction</header>
							<paragraph commented="no" display-inline="no-display-inline" id="idaca03700b2a3458da373e43ed7ee6165">
                <enum>(1)</enum>
                <header display-inline="yes-display-inline">In general</header>
                <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall grant a waiver from or a reduction of
				one or more fees assessed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a" proposed="true">subsection (a)</cato:entity-ref> where the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> finds
				that—</text>
								<subparagraph commented="no" display-inline="no-display-inline" id="id0605974517334d95abb436828ad5217f">
                  <enum>(A)</enum>
                  <text display-inline="yes-display-inline">the assessment of the fee would present a
				significant barrier to innovation because of limited resources available to
				such person or other circumstances;</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id748e3a4b940b4602a7fed665a4d4d2f9">
                  <enum>(B)</enum>
                  <text display-inline="yes-display-inline">the fees to be
				paid by such person will exceed the anticipated present and future costs
				incurred by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> in conducting the process for the review of animal
				drug applications for such person;</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id0888a19d88004833bc3af69869fd5f22">
                  <enum>(C)</enum>
                  <text display-inline="yes-display-inline">the animal drug application or supplemental
				animal drug application is intended solely to provide for use of the animal
				drug in—</text>
									<clause commented="no" display-inline="no-display-inline" id="ide819f3de5b8445eebfd87cb6df3ffdfb">
                    <enum>(i)</enum>
                    <text display-inline="yes-display-inline">a Type B medicated feed (as defined in
				<external-xref legal-doc="regulation" parsable-cite="cfr/21/558.3">section 558.3(b)(3)</external-xref> of title 21, Code of Federal Regulations (or any successor
				regulation)) intended for use in the manufacture of Type C free-choice
				medicated feeds; or</text>
									</clause>
                  <clause commented="no" display-inline="no-display-inline" id="ida97a890bfb924c4f97282e53e50429be">
                    <enum>(ii)</enum>
                    <text display-inline="yes-display-inline">a Type C free-choice medicated feed (as
				defined in <external-xref legal-doc="regulation" parsable-cite="cfr/21/558.3">section 558.3(b)(4)</external-xref> of title 21, Code of Federal Regulations (or any
				successor regulation));</text>
									</clause>
                </subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id54867149a9004d5fa36e326209f80ad0">
                  <enum>(D)</enum>
                  <text display-inline="yes-display-inline">the animal drug application or supplemental
				animal drug application is intended solely to provide for a minor use or minor
				species indication; or</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id27ee5fb886bf42fdb513d26ac1754466">
                  <enum>(E)</enum>
                  <text display-inline="yes-display-inline">the sponsor
				involved is a small business submitting its first animal drug application to
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> for review.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="idf1216e118c0a48c2941625019319b283">
                <enum>(2)</enum>
                <header display-inline="yes-display-inline">Use of standard costs</header>
                <text display-inline="yes-display-inline">In making the finding in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:d/p:1/sp:B" proposed="true">paragraph (1)(B)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				may use standard costs.</text>
							</paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="idac78667703e048a2a2b309c08878a132">
                <enum>(3)</enum>
                <header display-inline="yes-display-inline">Rules for small businesses</header>
								<subparagraph commented="no" display-inline="no-display-inline" id="id63490f3311f24674a2a20d163fa01089">
                  <enum>(A)</enum>
                  <header display-inline="yes-display-inline">Definition</header>
                  <text display-inline="yes-display-inline">In
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:d/p:1/sp:E" proposed="true">paragraph (1)(E)</cato:entity-ref>, the term <term>small business</term> means an entity that has
				fewer than 500 employees, including employees of affiliates.</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id8389047c675f4977af7588406623de9b">
                  <enum>(B)</enum>
                  <header display-inline="yes-display-inline">Waiver of application fee</header>
                  <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall waive under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:d/p:1/sp:E" proposed="true">paragraph (1)(E)</cato:entity-ref>
				the application fee for the first animal drug application that a small business
				or its affiliate submits to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> for review. After a small business or
				its affiliate is granted such a waiver, the small business or its affiliate
				shall pay application fees for all subsequent animal drug applications and
				supplemental animal drug applications for which safety or effectiveness data
				are required in the same manner as an entity that does not qualify as a small
				business.</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="ide87ea137ffb94c83ba6358425b8ae68b">
                  <enum>(C)</enum>
                  <header display-inline="yes-display-inline">Certification</header>
                  <text display-inline="yes-display-inline">The
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall require any person who applies for a waiver under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:d/p:1/sp:E" proposed="true">paragraph
				(1)(E)</cato:entity-ref> to certify their qualification for the waiver. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
				periodically publish in the Federal Register a list of persons making such
				certifications.</text>
								</subparagraph>
              </paragraph>
            </subsection>
            <subsection commented="no" display-inline="no-display-inline" id="ide7cd2c8d294d4fc3ae7c308c5a04b6f2">
              <enum>(e)</enum>
              <header display-inline="yes-display-inline">Effect of failure To pay fees</header>
              <text display-inline="yes-display-inline">An animal drug application or supplemental
				animal drug application submitted by a person subject to fees under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a" proposed="true">subsection
				(a)</cato:entity-ref> shall be considered incomplete and shall not be accepted for filing by the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> until all fees owed by such person have been paid. An investigational
				animal drug submission under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:739/p:5/sp:B" proposed="true">section 739(5)(B)</cato:entity-ref> that is submitted by a person
				subject to fees under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a" proposed="true">subsection (a)</cato:entity-ref> shall be considered incomplete and shall
				not be accepted for review by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> until all fees owed by such person
				have been paid. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may discontinue review of any animal drug
				application, supplemental animal drug application or investigational animal
				drug submission from a person if such person has not submitted for payment all
				fees owed under this section by 30 days after the date upon which they are
				due.</text>
						</subsection>
            <subsection commented="no" display-inline="no-display-inline" id="id65edffaa16784560a40ead49845e81e5">
              <enum>(f)</enum>
              <header display-inline="yes-display-inline">Assessment of fees</header>
							<paragraph commented="no" display-inline="no-display-inline" id="id8097173620504c51b2377b93e98f8166">
                <enum>(1)</enum>
                <header display-inline="yes-display-inline">Limitation</header>
                <text display-inline="yes-display-inline">Fees
				may not be assessed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a" proposed="true">subsection (a)</cato:entity-ref> for a fiscal year beginning after
				fiscal year 2003 unless appropriations for salaries and expenses of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food
				and Drug Administration</cato:entity-ref> for such fiscal year (excluding the amount of fees
				appropriated for such fiscal year) are equal to or greater than the amount of
				appropriations for the salaries and expenses of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug
				Administration</cato:entity-ref> for the fiscal year 2003 (excluding the amount of fees
				appropriated for such fiscal year) multiplied by the adjustment factor
				applicable to the fiscal year involved.</text>
							</paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="ide7984a1f0bf44d048c6f6fc03396fa82">
                <enum>(2)</enum>
                <header display-inline="yes-display-inline">Authority</header>
                <text display-inline="yes-display-inline">If the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> does not assess fees under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a" proposed="true">subsection (a)</cato:entity-ref> during any portion of a fiscal year because of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:f/p:1" proposed="true">paragraph (1)</cato:entity-ref> and
				if at a later date in such fiscal year the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may assess such fees, the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may assess and collect such fees, without any modification in the
				rate, for animal drug applications, supplemental animal drug applications,
				investigational animal drug submissions, animal drug sponsors, animal drug
				establishments and animal drug products at any time in such fiscal year
				notwithstanding the provisions of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a" proposed="true">subsection (a)</cato:entity-ref> relating to the date fees are
				to be paid.</text>
							</paragraph>
            </subsection>
            <subsection commented="no" display-inline="no-display-inline" id="id26b0ce484bc3479abb5a8698156becd0">
              <enum>(g)</enum>
              <header display-inline="yes-display-inline">Crediting and availability of fees</header>
							<paragraph commented="no" display-inline="no-display-inline" id="id69eefe8b0407495781fe5652401c79d4">
                <enum>(1)</enum>
                <header display-inline="yes-display-inline">In general</header>
                <text display-inline="yes-display-inline">Subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:g/p:2/sp:C" proposed="true">paragraph (2)(C)</cato:entity-ref>, fees authorized under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a" proposed="true">subsection (a)</cato:entity-ref> shall be collected and available for obligation only to the
				extent and in the amount provided in advance in appropriations Acts. Such fees
				are authorized to be appropriated to remain available until expended. Such sums
				as may be necessary may be transferred from the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref>
				salaries and expenses appropriation account without fiscal year limitation to
				such appropriation account for salary and expenses with such fiscal year
				limitation. The sums transferred shall be available solely for the process for
				the review of animal drug applications.</text>
							</paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="id9f693160d00841d9812c3b60ddd7ac5f">
                <enum>(2)</enum>
                <header display-inline="yes-display-inline">Collections and appropriation acts</header>
								<subparagraph commented="no" display-inline="no-display-inline" id="id1e7f16bd4e9244d19b3f9d9a1b05c393">
                  <enum>(A)</enum>
                  <header display-inline="yes-display-inline">In general</header>
                  <text display-inline="yes-display-inline">The fees authorized by this section—</text>
									<clause commented="no" display-inline="no-display-inline" id="id06bada831ef44b2b83d2b209e2b20282">
                    <enum>(i)</enum>
                    <text display-inline="yes-display-inline">subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:g/p:2/sp:C" proposed="true">subparagraph (C)</cato:entity-ref>, shall be
				collected and available in each fiscal year in an amount not to exceed the
				amount specified in appropriation Acts, or otherwise made available for
				obligation for such fiscal year, and</text>
									</clause>
                  <clause commented="no" display-inline="no-display-inline" id="id46588b6b48e84a3f83c15e128c4fd3b2">
                    <enum>(ii)</enum>
                    <text display-inline="yes-display-inline">shall be
				available to defray increases in the costs of the resources allocated for the
				process for the review of animal drug applications (including increases in such
				costs for an additional number of full-time equivalent positions in the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Department of Health and Human Services</cato:entity-ref> to be engaged in such process) over
				such costs, excluding costs paid from fees collected under this section, for
				fiscal year 2003 multiplied by the adjustment factor.</text>
									</clause>
                </subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id392449b0361a4c37b7b53aad1ef92fcb">
                  <enum>(B)</enum>
                  <header display-inline="yes-display-inline">Compliance</header>
                  <text display-inline="yes-display-inline">The
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall be considered to have met the requirements of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:720/ss:g/p:2/sp:A/cl:ii" proposed="true">subparagraph
				(A)(ii)</cato:entity-ref> in any fiscal year if the costs funded by appropriations and allocated
				for the process for the review of animal drug applications—</text>
									<clause commented="no" display-inline="no-display-inline" id="id403d638ecdd940a8b4b5df219a49f2c2">
                    <enum>(i)</enum>
                    <text display-inline="yes-display-inline">are not more than 3 percent below the level
				specified in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:720/ss:g/p:2/sp:A/cl:ii" proposed="true">subparagraph (A)(ii)</cato:entity-ref>; or</text>
									</clause>
                  <clause commented="no" display-inline="no-display-inline" id="id5d49f7d3dd7949dabc7af64aa5601d38">
                    <enum>(ii)</enum>
                    <subclause commented="no" display-inline="yes-display-inline" id="id843D35BAAB274BAFB62E986A7096C7C2">
                      <enum>(I)</enum>
                      <text display-inline="yes-display-inline">are more than 3 percent below the level
				specified in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:720/ss:g/p:2/sp:A/cl:ii" proposed="true">subparagraph (A)(ii)</cato:entity-ref>, and fees assessed for the fiscal year
				following the subsequent fiscal year are decreased by the amount in excess of 3
				percent by which such costs fell below the level specified in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:720/ss:g/p:2/sp:A/cl:ii" proposed="true">subparagraph
				(A)(ii)</cato:entity-ref>; and</text>
										</subclause>
                    <subclause commented="no" display-inline="no-display-inline" id="idB5FA6A04D5DF454B997DB044F9DFCE62" indent="up1">
                      <enum>(II)</enum>
                      <text display-inline="yes-display-inline">such costs are not more than 5 percent
				below the level specified in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:720/ss:g/p:2/sp:A/cl:ii" proposed="true">subparagraph (A)(ii)</cato:entity-ref>.</text>
										</subclause>
                  </clause>
                </subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id31dff28713af4d34bad74c8d4bee74b4">
                  <enum>(C)</enum>
                  <header display-inline="yes-display-inline">Provision for early payments</header>
                  <text display-inline="yes-display-inline">Payment of fees authorized under this
				section for a fiscal year, prior to the due date for such fees, may be accepted
				by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> in accordance with authority provided in advance in a prior
				year appropriations Act.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="id9edc07c1ec99401386901a6f38345481">
                <enum>(3)</enum>
                <header display-inline="yes-display-inline">Authorization of
				appropriations</header>
                <text display-inline="yes-display-inline">
                  <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="auth-auth-approp">For each of the fiscal years 2014 through 2018,
				there is authorized to be appropriated <cato:property name="purpose">for fees under <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740" proposed="true">this section</cato:entity-ref>
                    </cato:property> an amount
				equal to the <cato:funds-and-year amount="23600000" year="2014">total revenue amount determined under <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:b" proposed="true">subsection (b)</cato:entity-ref>
                    </cato:funds-and-year> <cato:funds-and-year amount="21600000" year="2015, 2016, 2017, 2018">for the
				fiscal year</cato:funds-and-year>, as adjusted or otherwise affected under <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:c" proposed="true">subsection (c)</cato:entity-ref> and
				<cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:g/p:4" proposed="true">paragraph (4)</cato:entity-ref>.</cato:entity>
                </text>
							</paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="idccfd5c44eb3448a68c4d6e6b4c9dd806">
                <enum>(4)</enum>
                <header display-inline="yes-display-inline">Offset of overcollections; recovery of
				collection shortfalls</header>
								<subparagraph commented="no" display-inline="no-display-inline" id="id184e5d32ed594ca0bf3ffd409d100a1c">
                  <enum>(A)</enum>
                  <header display-inline="yes-display-inline">Offset of overcollections</header>
                  <text display-inline="yes-display-inline">If the sum of the cumulative amount of fees
				collected under this section for fiscal years 2014 through 2016 and the amount
				of fees estimated to be collected under this section for fiscal year 2017
				(including any increased fee collections attributable to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:g/p:4/sp:B" proposed="true">subparagraph (B)</cato:entity-ref>),
				exceeds the cumulative amount appropriated pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:g/p:3" proposed="true">paragraph (3)</cato:entity-ref> for the
				fiscal years 2014 through 2017, the excess amount shall be credited to the
				appropriation account of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> as provided in
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:g/p:1" proposed="true">paragraph (1)</cato:entity-ref>, and shall be subtracted from the amount of fees that would
				otherwise be authorized to be collected under this section pursuant to
				appropriation Acts for fiscal year 2018.</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id59f70c4eda2b48a990d9c7b9ac351e11">
                  <enum>(B)</enum>
                  <header display-inline="yes-display-inline">Recovery of collection shortfalls</header>
									<clause commented="no" display-inline="no-display-inline" id="id104c67d7fb734180b2c3e8a8b1a865b4">
                    <enum>(i)</enum>
                    <header display-inline="yes-display-inline">Fiscal year 2016</header>
                    <text display-inline="yes-display-inline">For fiscal year 2016, the amount of fees otherwise
				authorized to be collected under this section shall be increased by the amount,
				if any, by which the amount collected under this section and appropriated for
				fiscal year 2014 falls below the amount of fees authorized for fiscal year 2014
				under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:g/p:3" proposed="true">paragraph (3)</cato:entity-ref>.</text>
									</clause>
                  <clause commented="no" display-inline="no-display-inline" id="id734261ab2af44cfe94750df06bcd059a">
                    <enum>(ii)</enum>
                    <header display-inline="yes-display-inline">Fiscal year 2017</header>
                    <text display-inline="yes-display-inline">For fiscal year 2017, the amount of fees otherwise
				authorized to be collected under this section shall be increased by the amount,
				if any, by which the amount collected under this section and appropriated for
				fiscal year 2015 falls below the amount of fees authorized for fiscal year 2015
				under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:g/p:3" proposed="true">paragraph (3)</cato:entity-ref>.</text>
									</clause>
                  <clause commented="no" display-inline="no-display-inline" id="idcce94146ddcd49a68e7c0fff8fff7738">
                    <enum>(iii)</enum>
                    <header display-inline="yes-display-inline">Fiscal year 2018</header>
                    <text display-inline="yes-display-inline">For fiscal year 2018, the amount of fees otherwise
				authorized to be collected under this section (including any reduction in the
				authorized amount under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:g/p:4/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>), shall be increased by the cumulative
				amount, if any, by which the amount collected under this section and
				appropriated for fiscal years 2016 and 2017 (including estimated collections
				for fiscal year 2017) falls below the cumulative amount of fees authorized
				under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:g/p:3" proposed="true">paragraph (3)</cato:entity-ref> for fiscal years 2016 and 2017.</text>
									</clause>
                </subparagraph>
              </paragraph>
            </subsection>
            <subsection commented="no" display-inline="no-display-inline" id="idc76efd22b8394a63903cc6e58714edf1">
              <enum>(h)</enum>
              <header display-inline="yes-display-inline">Collection of unpaid fees</header>
              <text display-inline="yes-display-inline">In any case where the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> does not
				receive payment of a fee assessed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a" proposed="true">subsection (a)</cato:entity-ref> within 30 days after it
				is due, such fee shall be treated as a claim of the United States Government
				subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc-chapter/31/37/II">subchapter II of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/31/37">chapter 37</external-xref> of title 31, United States Code</cato:entity-ref>.</text>
						</subsection>
            <subsection commented="no" display-inline="no-display-inline" id="idda35a235af3e4f8f9c8d98427c724d62">
              <enum>(i)</enum>
              <header display-inline="yes-display-inline">Written requests for waivers, reductions,
				and refunds</header>
              <text display-inline="yes-display-inline">To qualify for
				consideration for a waiver or reduction under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:d" proposed="true">subsection (d)</cato:entity-ref>, or for a refund
				of any fee collected in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a" proposed="true">subsection (a)</cato:entity-ref>, a person shall submit
				to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> a written request for such waiver, reduction, or refund not
				later than 180 days after such fee is due.</text>
						</subsection>
            <subsection commented="no" display-inline="no-display-inline" id="id711bcda79b1640eda8809e41b0caa566">
              <enum>(j)</enum>
              <header display-inline="yes-display-inline">Construction</header>
              <text display-inline="yes-display-inline">This
				section may not be construed to require that the number of full-time equivalent
				positions in the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Department of Health and Human Services</cato:entity-ref>, for officers,
				employees, and advisory committees not engaged in the process of the review of
				animal drug applications, be reduced to offset the number of officers,
				employees, and advisory committees so engaged.</text>
						</subsection>
            <subsection commented="no" display-inline="no-display-inline" id="id16bb5dd7abb14d298f632d69081702f3">
              <enum>(k)</enum>
              <header display-inline="yes-display-inline">Abbreviated new animal drug
				applications</header>
              <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				shall—</text>
							<paragraph commented="no" display-inline="no-display-inline" id="id33baecf53cf54a36b38df809eb9926cb">
                <enum>(1)</enum>
                <text display-inline="yes-display-inline">to the extent practicable, segregate the
				review of abbreviated new animal drug applications from the process for the
				review of animal drug applications; and</text>
							</paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="idfcf2953d5595412b81d55a821bdc4cf6">
                <enum>(2)</enum>
                <text display-inline="yes-display-inline">adopt other administrative procedures to
				ensure that review times of abbreviated new animal drug applications do not
				increase from their current level due to activities under the user fee
				program.</text>
							</paragraph>
            </subsection>
          </section>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</section>
      <section commented="no" display-inline="no-display-inline" id="idF95379A251544E6E81CF9BBCFDFA1C6E" section-type="subsequent-section">
        <enum>104.</enum>
        <header display-inline="yes-display-inline">Reauthorization; reporting
			 requirements</header>
        <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740A">Section
			 740A of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-13">21 U.S.C. 379j–13</external-xref>)</cato:entity> is amended
			 to read as follows:</text>
				<quoted-block display-inline="no-display-inline" id="id42045B5453184AC8B1E58DE58F9C326B" style="OLC">
					<section commented="no" display-inline="no-display-inline" id="id169ab2424afb43bba1e9aa0871d919b9" section-type="subsequent-section">
            <enum>740A.</enum>
            <header display-inline="yes-display-inline">Reauthorization; reporting
				requirements</header>
						<subsection commented="no" display-inline="no-display-inline" id="ide710374a1b3649a282c6a20d66db3469">
              <enum>(a)</enum>
              <header display-inline="yes-display-inline">Performance report</header>
              <text display-inline="yes-display-inline">Beginning with fiscal year 2014, not later
				than 120 days after the end of each fiscal year during which fees are collected
				under this part, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall prepare and submit to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="SSHR00">Committee on
				Health, Education, Labor, and Pensions of the Senate</cato:entity-ref> and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="HIF00">Committee on
				Energy and Commerce of the House of Representatives</cato:entity-ref> a report concerning the
				progress of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> in achieving the goals identified
				in the letters described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Animal Drug User Fee Amendments of 2013/s:101/ss:b">section 101(b) of the Animal Drug User Fee
				Amendments of 2013</cato:entity-ref> toward expediting the animal drug development process and
				the review of the new and supplemental animal drug applications and
				investigational animal drug submissions during such fiscal year, the future
				plans of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> for meeting the goals, the review
				times for abbreviated new animal drug applications, and the administrative
				procedures adopted by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> to ensure that review
				times for abbreviated new animal drug applications are not increased from their
				current level due to activities under the user fee program.</text>
						</subsection>
            <subsection commented="no" display-inline="no-display-inline" id="id036e8e685fd2433a9a150752fc6853c9">
              <enum>(b)</enum>
              <header display-inline="yes-display-inline">Fiscal report</header>
              <text display-inline="yes-display-inline">Beginning with fiscal year 2014, not later than 120 days
				after the end of each fiscal year during which fees are collected under this
				part, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall prepare and submit to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="SSHR00">Committee on Health,
				Education, Labor, and Pensions of the Senate</cato:entity-ref> and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="HIF00">Committee on Energy and
				Commerce of the House of Representatives</cato:entity-ref> a report on the implementation of the
				authority for such fees during such fiscal year and the use, by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and
				Drug Administration</cato:entity-ref>, of the fees collected during such fiscal year for which
				the report is made.</text>
						</subsection>
            <subsection commented="no" display-inline="no-display-inline" id="id70c74929fa794ceda549be2e4bcdb860">
              <enum>(c)</enum>
              <header display-inline="yes-display-inline">Public availability</header>
              <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall make the reports
				required under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740A/ss:a" proposed="true">subsections (a)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740A/ss:b" proposed="true">(b)</cato:entity-ref> available to the public on the Internet
				Web site of the Food and Drug Administration.</text>
						</subsection>
            <subsection commented="no" display-inline="no-display-inline" id="idebefb335a8394bb6b022f739b5489539">
              <enum>(d)</enum>
              <header display-inline="yes-display-inline">Reauthorization</header>
							<paragraph commented="no" display-inline="no-display-inline" id="id57095eef82914448879892c2b5cfe99c">
                <enum>(1)</enum>
                <header display-inline="yes-display-inline">Consultation</header>
                <text display-inline="yes-display-inline">In
				developing recommendations to present to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref> with respect to the
				goals, and plans for meeting the goals, for the process for the review of
				animal drug applications for the first 5 fiscal years after fiscal year 2018,
				and for the reauthorization of this part for such fiscal years, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				shall consult with—</text>
								<subparagraph commented="no" display-inline="no-display-inline" id="ide111af8ca37e4693b84ca1626c83cd47">
                  <enum>(A)</enum>
                  <text display-inline="yes-display-inline">the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="SSHR00">Committee on Health, Education, Labor,
				and Pensions of the Senate</cato:entity-ref>;</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id448d41d83bf441b3a1391bff9bad9137">
                  <enum>(B)</enum>
                  <text display-inline="yes-display-inline">the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="HIF00">Committee on Energy and Commerce of the
				House of Representatives</cato:entity-ref>;</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id07b24380644a4aabae82feedc049e120">
                  <enum>(C)</enum>
                  <text display-inline="yes-display-inline">scientific and academic experts;</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id9008aebf19cc479e8b2fd3c7e20d0f68">
                  <enum>(D)</enum>
                  <text display-inline="yes-display-inline">veterinary professionals;</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="idd5d4740bfc954e24b85d86514a3b9cf6">
                  <enum>(E)</enum>
                  <text display-inline="yes-display-inline">representatives of patient and consumer
				advocacy groups; and</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="idef604a0ab22e4a57b6ea8698e136787b">
                  <enum>(F)</enum>
                  <text display-inline="yes-display-inline">the regulated industry.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="id89f90dbdd5e04ec2aa435447045e507b">
                <enum>(2)</enum>
                <header display-inline="yes-display-inline">Prior public input</header>
                <text display-inline="yes-display-inline">Prior to beginning negotiations with the
				regulated industry on the reauthorization of this part, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				shall—</text>
								<subparagraph commented="no" display-inline="no-display-inline" id="idd1d66eb433a645658f2b64fc5667fa96">
                  <enum>(A)</enum>
                  <text display-inline="yes-display-inline">publish a notice in the Federal Register
				requesting public input on the reauthorization;</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id269baaa080b84fef91902ca8d2aa46a3">
                  <enum>(B)</enum>
                  <text display-inline="yes-display-inline">hold a public meeting at which the public
				may present its views on the reauthorization, including specific suggestions
				for changes to the goals referred to in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740A/ss:a" proposed="true">subsection (a)</cato:entity-ref>;</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id7496a4dca3e8451f85d7842dd3216a64">
                  <enum>(C)</enum>
                  <text display-inline="yes-display-inline">provide a period of 30 days after the
				public meeting to obtain written comments from the public suggesting changes to
				this part; and</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id67d013b5e00b4c48a9e36b7df2599129">
                  <enum>(D)</enum>
                  <text display-inline="yes-display-inline">publish the comments on the Food and Drug
				Administration’s Internet Web site.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="id9230d0a90c734dc5a1058fe99e46cfa9">
                <enum>(3)</enum>
                <header display-inline="yes-display-inline">Periodic consultation</header>
                <text display-inline="yes-display-inline">Not less frequently than once every 4
				months during negotiations with the regulated industry, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
				hold discussions with representatives of veterinary, patient, and consumer
				advocacy groups to continue discussions of their views on the reauthorization
				and their suggestions for changes to this part as expressed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740A/ss:d/p:2" proposed="true">paragraph
				(2)</cato:entity-ref>.</text>
							</paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="id57f685acb120400697565bc2d0b43fbc">
                <enum>(4)</enum>
                <header display-inline="yes-display-inline">Public review of
				recommendations</header>
                <text display-inline="yes-display-inline">After
				negotiations with the regulated industry, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall—</text>
								<subparagraph commented="no" display-inline="no-display-inline" id="idf9b35f1dc4d6427895456dc260e75775">
                  <enum>(A)</enum>
                  <text display-inline="yes-display-inline">present the recommendations developed under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740A/ss:d/p:1" proposed="true">paragraph (1)</cato:entity-ref> to the Congressional committees specified in such
				paragraph;</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="idcc769eebd7dc40a8bbe143ac09353cba">
                  <enum>(B)</enum>
                  <text display-inline="yes-display-inline">publish such recommendations in the Federal
				Register;</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="idac581df369e847d89cedc615ed466f56">
                  <enum>(C)</enum>
                  <text display-inline="yes-display-inline">provide for a period of 30 days for the
				public to provide written comments on such recommendations;</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id2cfd442b7abd45d9b39640e83aaaf812">
                  <enum>(D)</enum>
                  <text display-inline="yes-display-inline">hold a meeting at which the public may
				present its views on such recommendations; and</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id6f12127e7ba64095b14fef4d8d658e5a">
                  <enum>(E)</enum>
                  <text display-inline="yes-display-inline">after consideration of such public views
				and comments, revise such recommendations as necessary.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="idd01a91d0528f42da94f26ccb08545148">
                <enum>(5)</enum>
                <header display-inline="yes-display-inline">Transmittal of
				recommendations</header>
                <text display-inline="yes-display-inline">Not later
				than January 15, 2018, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall transmit to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref> the revised
				recommendations under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740A/ss:d/p:4" proposed="true">paragraph (4)</cato:entity-ref> a summary of the views and comments
				received under such paragraph, and any changes made to the recommendations in
				response to such views and comments.</text>
							</paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="ida076c7807f1d43238f245a5a5e6d8458">
                <enum>(6)</enum>
                <header display-inline="yes-display-inline">Minutes of negotiation meetings</header>
								<subparagraph commented="no" display-inline="no-display-inline" id="id9cb0747cfca04ad1ab544a53081714dc">
                  <enum>(A)</enum>
                  <header display-inline="yes-display-inline">Public availability</header>
                  <text display-inline="yes-display-inline">Before presenting the recommendations
				developed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740A/ss:d/p:1..5" proposed="true">paragraphs (1) through (5)</cato:entity-ref> to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
				make publicly available, on the Internet Web site of the Food and Drug
				Administration, minutes of all negotiation meetings conducted under this
				subsection between the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> and the regulated
				industry.</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id815564b6c0a64e78b0bf983cb962efa2">
                  <enum>(B)</enum>
                  <header display-inline="yes-display-inline">Content</header>
                  <text display-inline="yes-display-inline">The minutes described under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740A/ss:d/p:6/sp:A" proposed="true">subparagraph
				(A)</cato:entity-ref> shall summarize any substantive proposal made by any party to the
				negotiations as well as significant controversies or differences of opinion
				during the negotiations and their
				resolution.</text>
								</subparagraph>
              </paragraph>
            </subsection>
          </section>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</section>
      <section commented="no" display-inline="no-display-inline" id="idba28b0f6449e4cf594c392846a403b7d" section-type="subsequent-section">
        <enum>105.</enum>
        <header display-inline="yes-display-inline">Savings
			 clause</header>
        <text display-inline="no-display-inline">Notwithstanding the
			 amendments made by this title, <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/ch:VII/sch:C/pt:4">part 4 of subchapter C of chapter VII of the
			 Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-11">
              <cato:entity-ref entity-type="uscode" value="usc/21/379j–11/etseq">21 U.S.C. 379j–11 et seq.</cato:entity-ref>
            </external-xref>)</cato:entity>, as in effect
			 on the day before the date of the enactment of this title, shall continue to be
			 in effect with respect to animal drug applications and supplemental animal drug
			 applications (as defined in such part as of such day) that on or after October
			 1, 2008, but before October 1, 2013, were accepted by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug
			 Administration</cato:entity-ref> for filing with respect to assessing and collecting any fee
			 required by such part for a fiscal year prior to fiscal year 2014.</text>
			</section>
      <section commented="no" display-inline="no-display-inline" id="idc9d1267aec5c4c19b7d4aa9c166e8eee" section-type="subsequent-section">
        <enum>106.</enum>
        <header display-inline="yes-display-inline">Effective
			 date</header>
        <text display-inline="no-display-inline">The amendments made by
			 this title shall take effect on October 1, 2013, or the date of enactment of
			 this Act, whichever is later, except that fees under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/ch:VII/sch:C/pt:4">part 4 of subchapter C of
			 chapter VII of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref>, as amended by this
			 title, shall be assessed for all animal drug applications and supplemental
			 animal drug applications received on or after October 1, 2013, regardless of
			 the date of the enactment of this Act.</text>
			</section>
      <section commented="no" display-inline="no-display-inline" id="id0b82b2aad4a449f1a2d259581c5c328c" section-type="subsequent-section">
        <enum>107.</enum>
        <header display-inline="yes-display-inline">Sunset dates</header>
				<subsection commented="no" display-inline="no-display-inline" id="ida4a641c87d6f448487f5da62d52db76d">
          <enum>(a)</enum>
          <header display-inline="yes-display-inline">Authorization</header>
          <text display-inline="yes-display-inline">
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740" proposed="true">Section
			 740 of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-12">
                <cato:entity-ref entity-type="uscode" value="usc/21/379j–12" proposed="true">21 U.S.C. 379j–12</cato:entity-ref>
              </external-xref>)</cato:entity> shall cease
			 to be effective October 1, 2018.</text>
				</subsection>
        <subsection commented="no" display-inline="no-display-inline" id="id4cf78229349d409dbfb2ecdbcbe4b405">
          <enum>(b)</enum>
          <header display-inline="yes-display-inline">Reporting requirements</header>
          <text display-inline="yes-display-inline">
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740A" proposed="true">Section 740A of the Federal Food, Drug, and Cosmetic
			 Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-13">
                <cato:entity-ref entity-type="uscode" value="usc/21/379j–13" proposed="true">21 U.S.C. 379j–13</cato:entity-ref>
              </external-xref>)</cato:entity> shall cease to be effective January 31, 2019.</text>
				</subsection>
        <subsection commented="no" display-inline="no-display-inline" id="id4a9f8594497e4531a4856d553c4bbacf">
          <enum>(c)</enum>
          <header display-inline="yes-display-inline">Previous sunset provision</header>
					<paragraph commented="no" display-inline="no-display-inline" id="idF96D025B9B954D67B403EB31E8339400">
            <enum>(1)</enum>
            <header display-inline="yes-display-inline">In general</header>
            <text display-inline="yes-display-inline">
            <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Animal Drug User Fee Amendments of 2008/s:108">Section 108 of the Animal Drug User Fee Amendments of
			 2008</cato:entity-ref> (<external-xref legal-doc="public-law" parsable-cite="pl/110/316">Public Law 110–316</external-xref>)</cato:entity> is repealed.</text>
					</paragraph>
          <paragraph commented="no" display-inline="no-display-inline" id="id704437d4593445a1b663af92ade5d290">
            <enum>(2)</enum>
            <header display-inline="yes-display-inline">Conforming amendment</header>
            <text display-inline="yes-display-inline">The <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Animal Drug User Fee Amendments of 2008">Animal Drug User Fee Amendments of 2008</cato:entity-ref> (<cato:entity-ref entity-type="public-law" value="public-law/110/316">Public Law
			 110–316</cato:entity-ref>)</cato:entity> is amended in the table of contents in section 1, by striking the item
			 relating to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Animal Drug User Fee Amendments of 2008/s:108">section 108</cato:entity-ref>.</text>
					</paragraph>
        </subsection>
        <subsection commented="no" display-inline="no-display-inline" id="id9d1d603607f54f548b231acd56ef8fc7">
          <enum>(d)</enum>
          <header display-inline="yes-display-inline">Technical clarification</header>
          <text display-inline="yes-display-inline">Effective November 18, 2003, <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Animal Drug User Fee Act of 2003/s:5">section 5 of the
			 Animal Drug User Fee Act of 2003</cato:entity-ref> (<external-xref legal-doc="public-law" parsable-cite="pl/108/130">Public Law 108–130</external-xref>)</cato:entity> is repealed.</text>
				</subsection>
      </section>
    </title>
    <title commented="no" id="id887345CBA94A46EFAF59D050D74EF0E8" level-type="subsequent">
      <enum>II</enum>
      <header display-inline="yes-display-inline">Fees relating to generic animal
			 drugs</header>
			<section commented="no" display-inline="no-display-inline" id="id7BD7ADAD8E32489AACA44A75A67EB6D3" section-type="subsequent-section">
        <enum>201.</enum>
        <header display-inline="yes-display-inline">Short title; finding</header>
				<subsection commented="no" display-inline="no-display-inline" id="id5B7258CB595642B195BCA087E66A0A86">
          <enum>(a)</enum>
          <header display-inline="yes-display-inline">Short title</header>
          <text display-inline="yes-display-inline">This title may be cited as the
			 <quote>Animal Generic Drug User Fee Amendments of 2013</quote>.</text>
				</subsection>
        <subsection commented="no" display-inline="no-display-inline" id="id3676933E1331421F958CC0D6921A8692">
          <enum>(b)</enum>
          <header display-inline="yes-display-inline">Finding</header>
          <text display-inline="yes-display-inline">The fees authorized by this title will be
			 dedicated toward expediting the generic new animal drug development process and
			 the review of abbreviated applications for generic new animal drugs,
			 supplemental abbreviated applications for generic new animal drugs, and
			 investigational submissions for generic new animal drugs as set forth in the
			 goals identified in the letters from the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary of Health and Human Services</cato:entity-ref>
			 to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="HIF00">Chairman of the Committee on Energy and Commerce of the House of
			 Representatives</cato:entity-ref> and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="SSHR00">Chairman of the Committee on Health, Education, Labor,
			 and Pensions of the Senate</cato:entity-ref> as set forth in the Congressional Record.</text>
				</subsection>
      </section>
      <section commented="no" display-inline="no-display-inline" id="id105B4517DF0E45CC895D417541929E33" section-type="subsequent-section">
        <enum>202.</enum>
        <header display-inline="yes-display-inline">Authority to assess and use generic new
			 animal drug fees</header>
        <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741">Section 741 of the Federal Food, Drug, and
			 Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-21">21 U.S.C. 379j–21</external-xref>)</cato:entity> is amended to read as follows:</text>
				<quoted-block display-inline="no-display-inline" id="id317629433EE749E59AA433810759A5AE" style="OLC">
					<section commented="no" display-inline="no-display-inline" id="idCE203E7223C9448BA10C1238E884DF6F" section-type="subsequent-section">
            <enum>741.</enum>
            <header display-inline="yes-display-inline">Authority to assess and use generic new
				animal drug fees</header>
						<subsection commented="no" display-inline="no-display-inline" id="idA929B54902514A168CBA747A059C7C37">
              <enum>(a)</enum>
              <header display-inline="yes-display-inline">Types of fees</header>
              <text display-inline="yes-display-inline">Beginning with respect to fiscal year 2009, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				shall assess and collect fees in accordance with this section as
				follows:</text>
							<paragraph commented="no" display-inline="no-display-inline" id="idd033dcc8694346e9bfea5f744da4e5e8">
                <enum>(1)</enum>
                <header display-inline="yes-display-inline">Abbreviated application fee</header>
								<subparagraph commented="no" display-inline="no-display-inline" id="id64e19cdb78e846eb9618119a878bcb6e">
                  <enum>(A)</enum>
                  <header display-inline="yes-display-inline">In general</header>
                  <text display-inline="yes-display-inline">Each person that submits, on or after July 1, 2008, an
				abbreviated application for a generic new animal drug shall be subject to a fee
				as established in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:c" proposed="true">subsection (c)</cato:entity-ref> for such an application.</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="iddf1c179e7f89415cb864455241acc50c">
                  <enum>(B)</enum>
                  <header display-inline="yes-display-inline">Payment</header>
                  <text display-inline="yes-display-inline">The
				fee required by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a/p:1/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> shall be due upon submission of the
				abbreviated application.</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="idcacc9bc274074a8db26b6e5af3176db4">
                  <enum>(C)</enum>
                  <header display-inline="yes-display-inline">Exceptions</header>
									<clause commented="no" display-inline="no-display-inline" id="idf1a2fedb5ba147c694c99c050050e03d">
                    <enum>(i)</enum>
                    <header display-inline="yes-display-inline">Previously filed application</header>
                    <text display-inline="yes-display-inline">If an abbreviated application was submitted by a
				person that paid the fee for such application, was accepted for filing, and was
				not approved or was withdrawn (without a waiver or refund), the submission of
				an abbreviated application for the same product by the same person (or the
				person’s licensee, assignee, or successor) shall not be subject to a fee under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a/p:1/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>.</text>
									</clause>
                  <clause commented="no" display-inline="no-display-inline" id="idf6c5602f895c487eab23ff78be8b7782">
                    <enum>(ii)</enum>
                    <header display-inline="yes-display-inline">Certain abbreviated applications involving
				combination animal drugs</header>
                    <text display-inline="yes-display-inline">An
				abbreviated application which is subject to the criteria in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:d/p:4">section 512(d)(4)</cato:entity-ref>
				and submitted on or after October 1, 2013 shall be subject to a fee equal to 50
				percent of the amount of the abbreviated application fee established in
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:c" proposed="true">subsection (c)</cato:entity-ref>.</text>
									</clause>
                </subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id700c5176ac0f4e729575ac629c0538dd">
                  <enum>(D)</enum>
                  <header display-inline="yes-display-inline">Refund of fee if application refused for
				filing</header>
                  <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall refund 75
				percent of the fee paid under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a/p:1/sp:B" proposed="true">subparagraph (B)</cato:entity-ref> for any abbreviated application
				which is refused for filing.</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id52f66165be4740efa589fcf66f4f4231">
                  <enum>(E)</enum>
                  <header display-inline="yes-display-inline">Refund of fee if application
				withdrawn</header>
                  <text display-inline="yes-display-inline">If an abbreviated application is withdrawn
				after the application was filed, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may refund the fee or portion of
				the fee paid under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a/p:1/sp:B" proposed="true">subparagraph (B)</cato:entity-ref> if no substantial work was performed on the
				application after the application was filed. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall have the sole
				discretion to refund the fee under this subparagraph. A determination by the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> concerning a refund under this subparagraph shall not be
				reviewable.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="idfd11ae881c8a4a8395dfe4a2a77d51bd">
                <enum>(2)</enum>
                <header display-inline="yes-display-inline">Generic new animal drug product
				fee</header>
								<subparagraph commented="no" display-inline="no-display-inline" id="iddab15399c61c4d0a8035ebba52405e39">
                  <enum>(A)</enum>
                  <header display-inline="yes-display-inline">In general</header>
                  <text display-inline="yes-display-inline">Each person—</text>
									<clause commented="no" display-inline="no-display-inline" id="idAAC47F3697D44D29AC81C4CF403D37F4">
                    <enum>(i)</enum>
                    <text display-inline="yes-display-inline">who is named as
				the applicant in an abbreviated application or supplemental abbreviated
				application for a generic new animal drug product which has been submitted for
				listing under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510">section 510</cato:entity-ref>; and</text>
									</clause>
                  <clause commented="no" display-inline="no-display-inline" id="id22C71518F6FC452C98C0C0B94BC7D85A">
                    <enum>(ii)</enum>
                    <text display-inline="yes-display-inline">who, after
				September 1, 2008, had pending before the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> an abbreviated application
				or supplemental abbreviated application,</text>
									</clause>
                  <continuation-text commented="no" continuation-text-level="subparagraph">shall pay for each such generic
				new animal drug product the annual fee established in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:c" proposed="true">subsection (c)</cato:entity-ref>.</continuation-text>
                </subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id211fc9136c594c11ba4e35b782475d93">
                  <enum>(B)</enum>
                  <header display-inline="yes-display-inline">Payment; fee due date</header>
                  <text display-inline="yes-display-inline">Such fee shall be payable for the fiscal year in which the
				generic new animal drug product is first submitted for listing under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510">section
				510</cato:entity-ref>, or is submitted for relisting under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510">section 510</cato:entity-ref> if the generic new animal
				drug product has been withdrawn from listing and relisted. After such fee is
				paid for that fiscal year, such fee shall be due each subsequent fiscal year
				that the product remains listed, upon the later of—</text>
									<clause commented="no" display-inline="no-display-inline" id="id7bddf23393ad4b39b10d88411c43cad6">
                    <enum>(i)</enum>
                    <text display-inline="yes-display-inline">the first business day after the date of
				enactment of an appropriations Act providing for the collection and obligation
				of fees for such fiscal year under this section; or</text>
									</clause>
                  <clause commented="no" display-inline="no-display-inline" id="id8830eb3b7c8748c193ac55db8ec8f2cd">
                    <enum>(ii)</enum>
                    <text display-inline="yes-display-inline">January 31 of each year.</text>
									</clause>
                </subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id891f78304ddc40e0a2671e398b8eb9d8">
                  <enum>(C)</enum>
                  <header display-inline="yes-display-inline">Limitation</header>
                  <text display-inline="yes-display-inline">Such fee shall be paid only once for each
				generic new animal drug product for a fiscal year in which the fee is
				payable.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="id6557cb8279b544cbb0c55ab780769fc7">
                <enum>(3)</enum>
                <header display-inline="yes-display-inline">Generic new animal drug sponsor
				fee</header>
								<subparagraph commented="no" display-inline="no-display-inline" id="iddd8b31386bc8451f9cafcf8812045a00">
                  <enum>(A)</enum>
                  <header display-inline="yes-display-inline">In general</header>
                  <text display-inline="yes-display-inline">Each person—</text>
									<clause commented="no" display-inline="no-display-inline" id="id3d9927c3f8ca4d9a86d2ca1c3fea48ce">
                    <enum>(i)</enum>
                    <text display-inline="yes-display-inline">who meets the definition of a generic new
				animal drug sponsor within a fiscal year; and</text>
									</clause>
                  <clause commented="no" display-inline="no-display-inline" id="id6ed44938f43440c286c689f69dcdbf4d">
                    <enum>(ii)</enum>
                    <text display-inline="yes-display-inline">who, after
				September 1, 2008, had pending before the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> an abbreviated application,
				a supplemental abbreviated application, or an investigational
				submission,</text>
									</clause>
                  <continuation-text commented="no" continuation-text-level="subparagraph">shall be assessed an annual
				generic new animal drug sponsor fee as established under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:c" proposed="true">subsection (c)</cato:entity-ref>.</continuation-text>
                </subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id973e315abc5b4c83ba5c0ca8a28c2dd4">
                  <enum>(B)</enum>
                  <header display-inline="yes-display-inline">Payment; fee due date</header>
                  <text display-inline="yes-display-inline">Such fee shall be due each fiscal year upon
				the later of—</text>
									<clause commented="no" display-inline="no-display-inline" id="idf3f3c6043fcd42a8adc1d78c4f59d909">
                    <enum>(i)</enum>
                    <text display-inline="yes-display-inline">the first business day after the date of
				enactment of an appropriations Act providing for the collection and obligation
				of fees for such fiscal year under this section; or</text>
									</clause>
                  <clause commented="no" display-inline="no-display-inline" id="id7e94ffff524241c29c0f544d1b328f44">
                    <enum>(ii)</enum>
                    <text display-inline="yes-display-inline">January 31 of each year.</text>
									</clause>
                </subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id5beff016510541e2b04af8839e31f8b0">
                  <enum>(C)</enum>
                  <header display-inline="yes-display-inline">Amount of fee</header>
                  <text display-inline="yes-display-inline">Each generic new animal drug sponsor shall
				pay only 1 such fee each fiscal year, as follows:</text>
									<clause commented="no" display-inline="no-display-inline" id="id1e219392f0c9409ba632949563e83795">
                    <enum>(i)</enum>
                    <text display-inline="yes-display-inline">100 percent of the
				amount of the generic new animal drug sponsor fee published for that fiscal
				year under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:c" proposed="true">subsection (c)</cato:entity-ref> for an applicant with more than 6 approved
				abbreviated applications.</text>
									</clause>
                  <clause commented="no" display-inline="no-display-inline" id="ida54fb62d685f40789260736565e74c79">
                    <enum>(ii)</enum>
                    <text display-inline="yes-display-inline">75 percent of the
				amount of the generic new animal drug sponsor fee published for that fiscal
				year under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:c" proposed="true">subsection (c)</cato:entity-ref> for an applicant with more than 1 and fewer than 7
				approved abbreviated applications.</text>
									</clause>
                  <clause commented="no" display-inline="no-display-inline" id="idb071d68510344c6387857401259a5fca">
                    <enum>(iii)</enum>
                    <text display-inline="yes-display-inline">50 percent of
				the amount of the generic new animal drug sponsor fee published for that fiscal
				year under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:c" proposed="true">subsection (c)</cato:entity-ref> for an applicant with 1 or fewer approved abbreviated
				applications.</text>
									</clause>
                </subparagraph>
              </paragraph>
            </subsection>
            <subsection commented="no" display-inline="no-display-inline" id="id1c956cf667cb4f9ca80915cb7e2b8665">
              <enum>(b)</enum>
              <header display-inline="yes-display-inline">Fee amounts</header>
              <text display-inline="yes-display-inline">Subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:c" proposed="true">subsections (c)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:d" proposed="true">(d)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:f" proposed="true">(f)</cato:entity-ref>, and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:g" proposed="true">(g)</cato:entity-ref>, the fees
				required under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a" proposed="true">subsection (a)</cato:entity-ref> shall be established to generate fee revenue
				amounts as follows:</text>
							<paragraph commented="no" display-inline="no-display-inline" id="idb58dd700a9284e1a9d8f8fc7404cc390">
                <enum>(1)</enum>
                <header display-inline="yes-display-inline">Total fee revenues for application
				fees</header>
                <text display-inline="yes-display-inline">The total fee revenues to be
				collected in abbreviated application fees under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a/p:1" proposed="true">subsection (a)(1)</cato:entity-ref> shall be
				$1,832,000 for fiscal year 2014, $1,736,000 for fiscal year 2015, $1,857,000
				for fiscal year 2016, $1,984,000 for fiscal year 2017, and $2,117,000 for
				fiscal year 2018.</text>
							</paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="id5669b7ac40eb48b79412de7b1b69dc28">
                <enum>(2)</enum>
                <header display-inline="yes-display-inline">Total fee revenues for product
				fees</header>
                <text display-inline="yes-display-inline">The total fee revenues to be collected
				in generic new animal drug product fees under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a/p:2" proposed="true">subsection (a)(2)</cato:entity-ref> shall be
				$2,748,000 for fiscal year 2014, $2,604,000 for fiscal year 2015, $2,786,000
				for fiscal year 2016, $2,976,000 for fiscal year 2017, and $3,175,000 for
				fiscal year 2018.</text>
							</paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="id051a16f1c29d483f8b09af6298f78f2a">
                <enum>(3)</enum>
                <header display-inline="yes-display-inline">Total fee revenues for sponsor
				fees</header>
                <text display-inline="yes-display-inline">The total fee revenues to be collected
				in generic new animal drug sponsor fees under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a/p:3" proposed="true">subsection (a)(3)</cato:entity-ref> shall be
				$2,748,000 for fiscal year 2014, $2,604,000 for fiscal year 2015, $2,786,000
				for fiscal year 2016, $2,976,000 for fiscal year 2017, and $3,175,000 for
				fiscal year 2018.</text>
							</paragraph>
            </subsection>
            <subsection commented="no" display-inline="no-display-inline" id="idf6f2311b96bd43de92f540e7ea172f1b">
              <enum>(c)</enum>
              <header display-inline="yes-display-inline">Annual fee setting; adjustments</header>
							<paragraph commented="no" display-inline="no-display-inline" id="idb497e2af466147f28ffd9808017b1da2">
                <enum>(1)</enum>
                <header display-inline="yes-display-inline">Annual fee setting</header>
                <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall establish, 60 days before the start
				of each fiscal year beginning after September 30, 2008, for that fiscal year,
				abbreviated application fees, generic new animal drug sponsor fees, and generic
				new animal drug product fees, based on the revenue amounts established under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:b" proposed="true">subsection (b)</cato:entity-ref> and the adjustments provided under this subsection.</text>
							</paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="id2b530be4ba344a7c8472d1472619bf1e">
                <enum>(2)</enum>
                <header display-inline="yes-display-inline">Workload adjustment</header>
                <text display-inline="yes-display-inline">The fee revenues shall be adjusted each
				fiscal year after fiscal year 2014 to reflect changes in review workload. With
				respect to such adjustment:</text>
								<subparagraph commented="no" display-inline="no-display-inline" id="idce55f0013c2843629bc3559c17c3ff6d">
                  <enum>(A)</enum>
                  <text display-inline="yes-display-inline">This adjustment
				shall be determined by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> based on a weighted average of the change
				in the total number of abbreviated applications for generic new animal drugs,
				manufacturing supplemental abbreviated applications for generic new animal
				drugs, investigational generic new animal drug study submissions, and
				investigational generic new animal drug protocol submissions submitted to the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall publish in the Federal Register the fees
				resulting from this adjustment and the supporting methodologies.</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="idc839937aeed44f2398c5cd749fee45df">
                  <enum>(B)</enum>
                  <text display-inline="yes-display-inline">Under no
				circumstances shall this workload adjustment result in fee revenues for a
				fiscal year that are less than the fee revenues for that fiscal year
				established in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:b" proposed="true">subsection (b)</cato:entity-ref>.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="id79f461a2102d4ba5ae16865000a62050">
                <enum>(3)</enum>
                <header display-inline="yes-display-inline">Final year adjustment</header>
                <text display-inline="yes-display-inline">For fiscal year 2018, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may, in addition
				to other adjustments under this subsection, further increase the fees under
				this section, if such an adjustment is necessary, to provide for up to 3 months
				of operating reserves of carryover user fees for the process for the review of
				abbreviated applications for generic new animal drugs for the first 3 months of
				fiscal year 2019. If the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> has carryover balances
				for the process for the review of abbreviated applications for generic new
				animal drugs in excess of 3 months of such operating reserves, then this
				adjustment shall not be made. If this adjustment is necessary, then the
				rationale for the amount of the increase shall be contained in the annual
				notice setting fees for fiscal year 2018.</text>
							</paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="idab55f7fd91134a609c1f3553647115d0">
                <enum>(4)</enum>
                <header display-inline="yes-display-inline">Limit</header>
                <text display-inline="yes-display-inline">The total amount of fees charged, as
				adjusted under this subsection, for a fiscal year may not exceed the total
				costs for such fiscal year for the resources allocated for the process for the
				review of abbreviated applications for generic new animal drugs.</text>
							</paragraph>
            </subsection>
            <subsection commented="no" display-inline="no-display-inline" id="id474bf912dc054a5394e194a0c8ccd9d1">
              <enum>(d)</enum>
              <header display-inline="yes-display-inline">Fee waiver or reduction</header>
              <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall grant a waiver from or a reduction
				of 1 or more fees assessed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a" proposed="true">subsection (a)</cato:entity-ref> where the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> finds that
				the generic new animal drug is intended solely to provide for a minor use or
				minor species indication.</text>
						</subsection>
            <subsection commented="no" display-inline="no-display-inline" id="idd9cb7aedcb3d4858b093b99de0a4b2f7">
              <enum>(e)</enum>
              <header display-inline="yes-display-inline">Effect of failure To pay fees</header>
              <text display-inline="yes-display-inline">An abbreviated application for a generic new
				animal drug submitted by a person subject to fees under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a" proposed="true">subsection (a)</cato:entity-ref> shall be
				considered incomplete and shall not be accepted for filing by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				until all fees owed by such person have been paid. An investigational
				submission for a generic new animal drug that is submitted by a person subject
				to fees under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a" proposed="true">subsection (a)</cato:entity-ref> shall be considered incomplete and shall not be
				accepted for review by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> until all fees owed by such person have
				been paid. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may discontinue review of any abbreviated application
				for a generic new animal drug, supplemental abbreviated application for a
				generic new animal drug, or investigational submission for a generic new animal
				drug from a person if such person has not submitted for payment all fees owed
				under this section by 30 days after the date upon which they are due.</text>
						</subsection>
            <subsection commented="no" display-inline="no-display-inline" id="idb22582a4cdf04bd8babc79b17fd0c976">
              <enum>(f)</enum>
              <header display-inline="yes-display-inline">Assessment of fees</header>
							<paragraph commented="no" display-inline="no-display-inline" id="id9edc3a6a8b1344e084165fab3c9608df">
                <enum>(1)</enum>
                <header display-inline="yes-display-inline">Limitation</header>
                <text display-inline="yes-display-inline">Fees
				may not be assessed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a" proposed="true">subsection (a)</cato:entity-ref> for a fiscal year beginning after
				fiscal year 2008 unless appropriations for salaries and expenses of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food
				and Drug Administration</cato:entity-ref> for such fiscal year (excluding the amount of fees
				appropriated for such fiscal year) are equal to or greater than the amount of
				appropriations for the salaries and expenses of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug
				Administration</cato:entity-ref> for the fiscal year 2003 (excluding the amount of fees
				appropriated for such fiscal year) multiplied by the adjustment factor
				applicable to the fiscal year involved.</text>
							</paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="id9a9badbc35d5453db9629e9ff10fb752">
                <enum>(2)</enum>
                <header display-inline="yes-display-inline">Authority</header>
                <text display-inline="yes-display-inline">If
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> does not assess fees under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a" proposed="true">subsection (a)</cato:entity-ref> during any portion of a
				fiscal year because of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:f/p:1" proposed="true">paragraph (1)</cato:entity-ref> and if at a later date in such fiscal year
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may assess such fees, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may assess and collect such
				fees, without any modification in the rate, for abbreviated applications,
				generic new animal drug sponsors, and generic new animal drug products at any
				time in such fiscal year notwithstanding the provisions of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a" proposed="true">subsection (a)</cato:entity-ref>
				relating to the date fees are to be paid.</text>
							</paragraph>
            </subsection>
            <subsection commented="no" display-inline="no-display-inline" id="idfb4a0834e4e44bca971de9ef32b1cb8a">
              <enum>(g)</enum>
              <header display-inline="yes-display-inline">Crediting and availability of fees</header>
							<paragraph commented="no" display-inline="no-display-inline" id="id5b018b8f434347bcbbc30f69a9b09049">
                <enum>(1)</enum>
                <header display-inline="yes-display-inline">In general</header>
                <text display-inline="yes-display-inline">Subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:g/p:2/sp:C" proposed="true">paragraph (2)(C)</cato:entity-ref>, fees authorized under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a" proposed="true">subsection (a)</cato:entity-ref> shall be collected and available for obligation only to the
				extent and in the amount provided in advance in appropriations Acts. Such fees
				are authorized to be appropriated to remain available until expended. Such sums
				as may be necessary may be transferred from the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref>
				salaries and expenses appropriation account without fiscal year limitation to
				such appropriation account for salary and expenses with such fiscal year
				limitation. The sums transferred shall be available solely for the process for
				the review of abbreviated applications for generic new animal drugs.</text>
							</paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="idc9b1a94605274f0e907affff1e4955c1">
                <enum>(2)</enum>
                <header display-inline="yes-display-inline">Collections and appropriation acts</header>
								<subparagraph commented="no" display-inline="no-display-inline" id="id9062c4e0e546425985494248120ca399">
                  <enum>(A)</enum>
                  <header display-inline="yes-display-inline">In general</header>
                  <text display-inline="yes-display-inline">The fees authorized by this section—</text>
									<clause commented="no" display-inline="no-display-inline" id="id347363eabb5742ed8aa7e3ebe4710571">
                    <enum>(i)</enum>
                    <text display-inline="yes-display-inline">subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:g/p:2/sp:C" proposed="true">subparagraph (C)</cato:entity-ref>, shall be
				collected and available in each fiscal year in an amount not to exceed the
				amount specified in appropriation Acts, or otherwise made available for
				obligation for such fiscal year; and</text>
									</clause>
                  <clause commented="no" display-inline="no-display-inline" id="ide9db51ba72164628b296549fe1ed056a">
                    <enum>(ii)</enum>
                    <text display-inline="yes-display-inline">shall be
				available to defray increases in the costs of the resources allocated for the
				process for the review of abbreviated applications for generic new animal drugs
				(including increases in such costs for an additional number of full-time
				equivalent positions in the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Department of Health and Human Services</cato:entity-ref> to be
				engaged in such process) over such costs, excluding costs paid from fees
				collected under this section, for fiscal year 2008 multiplied by the adjustment
				factor.</text>
									</clause>
                </subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="idd23dbbcd51834e5889d81909ce62b7ae">
                  <enum>(B)</enum>
                  <header display-inline="yes-display-inline">Compliance</header>
                  <text display-inline="yes-display-inline">The
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall be considered to have met the requirements of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:g/p:2/sp:A/cl:ii" proposed="true">subparagraph
				(A)(ii)</cato:entity-ref> in any fiscal year if the costs funded by appropriations and allocated
				for the process for the review of abbreviated applications for generic new
				animal drugs—</text>
									<clause commented="no" display-inline="no-display-inline" id="id4fb5d0dd6a4f489e9fecaeae3097a116">
                    <enum>(i)</enum>
                    <text display-inline="yes-display-inline">are not more than 3 percent below the level
				specified in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:g/p:2/sp:A/cl:ii" proposed="true">subparagraph (A)(ii)</cato:entity-ref>; or</text>
									</clause>
                  <clause commented="no" display-inline="no-display-inline" id="id64f07a2293324659bd822cce3a163897">
                    <enum>(ii)</enum>
                    <subclause commented="no" display-inline="yes-display-inline" id="id1577C26DF6A14192927D1A054851AF0E">
                      <enum>(I)</enum>
                      <text display-inline="yes-display-inline">are more than 3 percent below the level
				specified in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:g/p:2/sp:A/cl:ii" proposed="true">subparagraph (A)(ii)</cato:entity-ref>, and fees assessed for the fiscal year
				following the subsequent fiscal year are decreased by the amount in excess of 3
				percent by which such costs fell below the level specified in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:g/p:2/sp:A/cl:ii" proposed="true">subparagraph
				(A)(ii)</cato:entity-ref>; and</text>
										</subclause>
                    <subclause commented="no" display-inline="no-display-inline" id="id655045F5D8054D87866A62190C14BEE1" indent="up1">
                      <enum>(II)</enum>
                      <text display-inline="yes-display-inline">such costs are not more than 5 percent
				below the level specified in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:g/p:2/sp:A/cl:ii" proposed="true">subparagraph (A)(ii)</cato:entity-ref>.</text>
										</subclause>
                  </clause>
                </subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id19580c37f8ff4d26ad08a56edbba00a9">
                  <enum>(C)</enum>
                  <header display-inline="yes-display-inline">Provision for early payments</header>
                  <text display-inline="yes-display-inline">Payment of fees authorized under this
				section for a fiscal year, prior to the due date for such fees, may be accepted
				by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> in accordance with authority provided in advance in a prior
				year appropriations Act.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="idabfe73e158f249abb0232b9ef342c788">
                <enum>(3)</enum>
                <header display-inline="yes-display-inline">Authorization of
				appropriations</header>
                <text display-inline="yes-display-inline">
                <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="auth-auth-approp">There are authorized to be appropriated <cato:property name="purpose">for fees
				under <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741" proposed="true">this section</cato:entity-ref>
                    </cato:property>—</cato:entity>
              </text>
								<subparagraph commented="no" display-inline="no-display-inline" id="idac5784dfb4ef44e893b26b7cde670052">
                  <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="auth-auth-approp">
                    <enum>(A)</enum>
                  <text display-inline="yes-display-inline">
                    <cato:funds-and-year amount="7328000" year="2014">$7,328,000 for
				fiscal year 2014</cato:funds-and-year>;</text>
                  </cato:entity>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="idd10cd8580e5347f9ad83be3857ca567e">
                  <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="auth-auth-approp">
                    <enum>(B)</enum>
                  <text display-inline="yes-display-inline">
                    <cato:funds-and-year amount="6944000" year="2015">$6,944,000 for
				fiscal year 2015</cato:funds-and-year>;</text>
                  </cato:entity>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="idef95bb14183f45168b8ef8e5500fc69d">
                  <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="auth-auth-approp">
                    <enum>(C)</enum>
                  <text display-inline="yes-display-inline">
                    <cato:funds-and-year amount="7429000" year="2016">$7,429,000 for
				fiscal year 2016</cato:funds-and-year>;</text>
                  </cato:entity>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id70956af7bdf146d9bb768f9aee6dc5a5">
                  <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="auth-auth-approp">
                    <enum>(D)</enum>
                  <text display-inline="yes-display-inline">
                    <cato:funds-and-year amount="7936000" year="2017">$7,936,000 for
				fiscal year 2017</cato:funds-and-year>; and</text>
                  </cato:entity>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id4d2c2be7c3eb425d86e3526101b3071c">
                  <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="auth-auth-approp">
                    <enum>(E)</enum>
                  <text display-inline="yes-display-inline">
                    <cato:funds-and-year amount="8467000" year="2018">$8,467,000 for
				fiscal year 2018</cato:funds-and-year>;</text>
                  </cato:entity>
								</subparagraph>
                <continuation-text commented="no" continuation-text-level="paragraph">as adjusted to reflect adjustments in
				the total fee revenues made under this section and changes in the total amounts
				collected by abbreviated application fees, generic new animal drug sponsor
				fees, and generic new animal drug product fees.</continuation-text>
              </paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="id2aa2ca2dae8c4cb69c85a6a8d27d64fe">
                <enum>(4)</enum>
                <header display-inline="yes-display-inline">Offset</header>
                <text display-inline="yes-display-inline">If
				the sum of the cumulative amount of fees collected under this section for the
				fiscal years 2014 through 2016 and the amount of fees estimated to be collected
				under this section for fiscal year 2017 exceeds the cumulative amount
				appropriated under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:g/p:3" proposed="true">paragraph (3)</cato:entity-ref> for the fiscal years 2014 through 2017, the
				excess amount shall be credited to the appropriation account of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and
				Drug Administration</cato:entity-ref> as provided in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:g/p:1" proposed="true">paragraph (1)</cato:entity-ref>, and shall be subtracted from
				the amount of fees that would otherwise be authorized to be collected under
				this section pursuant to appropriation Acts for fiscal year 2018.</text>
							</paragraph>
            </subsection>
            <subsection commented="no" display-inline="no-display-inline" id="id985851c562cc46b7bee05be65b7538b3">
              <enum>(h)</enum>
              <header display-inline="yes-display-inline">Collection of unpaid fees</header>
              <text display-inline="yes-display-inline">In any case where the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> does not
				receive payment of a fee assessed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a" proposed="true">subsection (a)</cato:entity-ref> within 30 days after it
				is due, such fee shall be treated as a claim of the United States Government
				subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc-chapter/31/37/II">subchapter II of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/31/37">chapter 37</external-xref> of title 31, United States Code</cato:entity-ref>.</text>
						</subsection>
            <subsection commented="no" display-inline="no-display-inline" id="id5e73490d23ae4a99bb861fae59b1c633">
              <enum>(i)</enum>
              <header display-inline="yes-display-inline">Written requests for waivers, reductions,
				and refunds</header>
              <text display-inline="yes-display-inline">To qualify for
				consideration for a waiver or reduction under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:d" proposed="true">subsection (d)</cato:entity-ref>, or for a refund
				of any fee collected in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a" proposed="true">subsection (a)</cato:entity-ref>, a person shall submit
				to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> a written request for such waiver, reduction, or refund not
				later than 180 days after such fee is due.</text>
						</subsection>
            <subsection commented="no" display-inline="no-display-inline" id="id29448b8b6ce54925be18ca43cca6dc34">
              <enum>(j)</enum>
              <header display-inline="yes-display-inline">Construction</header>
              <text display-inline="yes-display-inline">This
				section may not be construed to require that the number of full-time equivalent
				positions in the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Department of Health and Human Services</cato:entity-ref>, for officers,
				employees, and advisory committees not engaged in the process of the review of
				abbreviated applications for generic new animal drugs, be reduced to offset the
				number of officers, employees, and advisory committees so engaged.</text>
						</subsection>
            <subsection commented="no" display-inline="no-display-inline" id="idBA43A3FF5D0B4A07A6EBEDE134DBD544">
              <enum>(k)</enum>
              <header display-inline="yes-display-inline">Definitions</header>
              <text display-inline="yes-display-inline">In
				this section and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:742" proposed="true">section 742</cato:entity-ref>:</text>
							<paragraph commented="no" display-inline="no-display-inline" id="id9e789c630f534fc1a17705f4711f20db">
                <enum>(1)</enum>
                <header display-inline="yes-display-inline">Abbreviated application for a generic new
				animal drug</header>
                <text display-inline="yes-display-inline">The terms
				<quote>abbreviated application for a generic new animal drug</quote> and
				<quote>abbreviated application</quote> mean an abbreviated application for the
				approval of any generic new animal drug submitted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:b/p:2">section 512(b)(2)</cato:entity-ref>. Such
				term does not include a supplemental abbreviated application for a generic new
				animal drug.</text>
							</paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="ida30b674c75294162b443730015f16a0c">
                <enum>(2)</enum>
                <header display-inline="yes-display-inline">Adjustment factor</header>
                <text display-inline="yes-display-inline">The term <term>adjustment factor</term>
				applicable to a fiscal year is the Consumer Price Index for all urban consumers
				(all items; United States city average) for October of the preceding fiscal
				year divided by—</text>
								<subparagraph commented="no" display-inline="no-display-inline" id="iddc627bb6c4f14deead951018b3911e85">
                  <enum>(A)</enum>
                  <text display-inline="yes-display-inline">for purposes of
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:f/p:1" proposed="true">subsection (f)(1)</cato:entity-ref>, such Index for October 2002; and</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="idf3c77447412d4cf6b311d82382553bcc">
                  <enum>(B)</enum>
                  <text display-inline="yes-display-inline">for purposes of
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:g/p:2/sp:A/cl:ii" proposed="true">subsection (g)(2)(A)(ii)</cato:entity-ref>, such Index for October 2007.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="id5673217cf52d44d59d2788efbdfd28dc">
                <enum>(3)</enum>
                <header display-inline="yes-display-inline">Costs of resources allocated for the
				process for the review of abbreviated applications for generic new animal
				drugs</header>
                <text display-inline="yes-display-inline">The term <term>costs of
				resources allocated for the process for the review of abbreviated applications
				for generic new animal drugs</term> means the expenses in connection with the
				process for the review of abbreviated applications for generic new animal drugs
				for—</text>
								<subparagraph commented="no" display-inline="no-display-inline" id="idb6172e6188464671aba1cd8e4c8cf6dd">
                  <enum>(A)</enum>
                  <text display-inline="yes-display-inline">officers and
				employees of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref>, contractors of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug
				Administration</cato:entity-ref>, advisory committees consulted with respect to the review of
				specific abbreviated applications, supplemental abbreviated applications, or
				investigational submissions, and costs related to such officers, employees,
				committees, and contractors, including costs for travel, education, and
				recruitment and other personnel activities;</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id284f904c024147579ef83105e08e3c5e">
                  <enum>(B)</enum>
                  <text display-inline="yes-display-inline">management of information, and the
				acquisition, maintenance, and repair of computer resources;</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id86ce78a8844748a0b5cc9bb6cc761dff">
                  <enum>(C)</enum>
                  <text display-inline="yes-display-inline">leasing, maintenance, renovation, and
				repair of facilities and acquisition, maintenance, and repair of fixtures,
				furniture, scientific equipment, and other necessary materials and supplies;
				and</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id17faa74bca3b4c2aa225ba900b4a3bc2">
                  <enum>(D)</enum>
                  <text display-inline="yes-display-inline">collecting fees under this section and
				accounting for resources allocated for the review of abbreviated applications,
				supplemental abbreviated applications, and investigational submissions.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="id20b1eb3b785c4ec390293f0af646feab">
                <enum>(4)</enum>
                <header display-inline="yes-display-inline">Final dosage form</header>
                <text display-inline="yes-display-inline">The term <term>final dosage form</term>
				means, with respect to a generic new animal drug product, a finished dosage
				form which is approved for administration to an animal without substantial
				further manufacturing. Such term includes generic new animal drug products
				intended for mixing in animal feeds.</text>
							</paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="id272826959c1744dcb5bed307340b9b2c">
                <enum>(5)</enum>
                <header display-inline="yes-display-inline">Generic new animal drug</header>
                <text display-inline="yes-display-inline">The term <term>generic new animal
				drug</term> means a new animal drug that is the subject of an abbreviated
				application.</text>
							</paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="id58927ba3757e4d39a57beee909079257">
                <enum>(6)</enum>
                <header display-inline="yes-display-inline">Generic new animal drug
				product</header>
                <text display-inline="yes-display-inline">The term
				<term>generic new animal drug product</term> means each specific strength or
				potency of a particular active ingredient or ingredients in final dosage form
				marketed by a particular manufacturer or distributor, which is uniquely
				identified by the labeler code and product code portions of the national drug
				code, and for which an abbreviated application for a generic new animal drug or
				a supplemental abbreviated application has been approved.</text>
							</paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="id44ea039cf7554eab87ade377979465d6">
                <enum>(7)</enum>
                <header display-inline="yes-display-inline">Generic new animal drug
				sponsor</header>
                <text display-inline="yes-display-inline">The term <term>generic new animal drug
				sponsor</term> means either an applicant named in an abbreviated application
				for a generic new animal drug that has not been withdrawn by the applicant and
				for which approval has not been withdrawn by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, or a person who has
				submitted an investigational submission for a generic new animal drug that has
				not been terminated or otherwise rendered inactive by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>.</text>
							</paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="idfde766ad6a094af99ff2af00b289ee00">
                <enum>(8)</enum>
                <header display-inline="yes-display-inline">Investigational submission for a generic
				new animal drug</header>
                <text display-inline="yes-display-inline">The terms
				<term>investigational submission for a generic new animal drug</term> and
				<quote>investigational submission</quote> mean—</text>
								<subparagraph commented="no" display-inline="no-display-inline" id="id5b080929c7b0475391d5f38fee5aaf53">
                  <enum>(A)</enum>
                  <text display-inline="yes-display-inline">the filing of a
				claim for an investigational exemption under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:j">section 512(j)</cato:entity-ref> for a generic new
				animal drug intended to be the subject of an abbreviated application or a
				supplemental abbreviated application; or</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id7b92f5fd2e404d55a274cd8bd2ab2253">
                  <enum>(B)</enum>
                  <text display-inline="yes-display-inline">the submission of
				information for the purpose of enabling the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> to evaluate the safety or
				effectiveness of a generic new animal drug in the event of the filing of an
				abbreviated application or supplemental abbreviated application for such
				drug.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="id762a596bef624fce92f8f6688bb0ef3b">
                <enum>(9)</enum>
                <header display-inline="yes-display-inline">Person</header>
                <text display-inline="yes-display-inline">The
				term <term>person</term> includes an affiliate thereof (as such term is defined
				in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:735/p:11">section 735(11)</cato:entity-ref>).</text>
							</paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="idcef769cd12b94d8790c5c79ae91e12ce">
                <enum>(10)</enum>
                <header display-inline="yes-display-inline">Process for the review of abbreviated
				applications for generic new animal drugs</header>
                <text display-inline="yes-display-inline">The term <term>process for the review of abbreviated
				applications for generic new animal drugs</term> means the following activities
				of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> with respect to the review of abbreviated applications,
				supplemental abbreviated applications, and investigational submissions:</text>
								<subparagraph commented="no" display-inline="no-display-inline" id="id1d28224fcbba42f78f55cd33f84cdb7f">
                  <enum>(A)</enum>
                  <text display-inline="yes-display-inline">The activities necessary for the review of
				abbreviated applications, supplemental abbreviated applications, and
				investigational submissions.</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="idca7ad63ac97d4c4b9af9c27fbc472598">
                  <enum>(B)</enum>
                  <text display-inline="yes-display-inline">The issuance of action letters which
				approve abbreviated applications or supplemental abbreviated applications or
				which set forth in detail the specific deficiencies in abbreviated
				applications, supplemental abbreviated applications, or investigational
				submissions and, where appropriate, the actions necessary to place such
				applications, supplemental applications, or submissions in condition for
				approval.</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id6b7613a72e984e13a81702dc0a34d4d6">
                  <enum>(C)</enum>
                  <text display-inline="yes-display-inline">The inspection of
				generic new animal drug establishments and other facilities undertaken as part
				of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary’s</cato:entity-ref> review of pending abbreviated applications, supplemental
				abbreviated applications, and investigational submissions.</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id27e26d94202a4fb1a715b9901fb0b98e">
                  <enum>(D)</enum>
                  <text display-inline="yes-display-inline">Monitoring of research conducted in
				connection with the review of abbreviated applications, supplemental
				abbreviated applications, and investigational submissions.</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id1f297d9205094f2e9f3f0ec77f835af8">
                  <enum>(E)</enum>
                  <text display-inline="yes-display-inline">The development of regulations and policy
				related to the review of abbreviated applications, supplemental abbreviated
				applications, and investigational submissions.</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="idbbdb71b7975c4d2cae850f74a353f26d">
                  <enum>(F)</enum>
                  <text display-inline="yes-display-inline">Development of standards for products
				subject to review.</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="idfe37190931f943e8986405691c20be94">
                  <enum>(G)</enum>
                  <text display-inline="yes-display-inline">Meetings between the agency and the generic
				new animal drug sponsor.</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id682dd24a3be843ecb77a23b85545731f">
                  <enum>(H)</enum>
                  <text display-inline="yes-display-inline">Review of advertising and labeling prior to
				approval of an abbreviated application or supplemental abbreviated application,
				but not after such application has been approved.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="id3415d393a8314ab99d600513ca224815">
                <enum>(11)</enum>
                <header display-inline="yes-display-inline">Supplemental abbreviated application for
				generic new animal drug</header>
                <text display-inline="yes-display-inline">The
				terms <quote>supplemental abbreviated application for a generic new animal
				drug</quote> and <quote>supplemental abbreviated application</quote> mean a
				request to the Secretary to approve a change in an approved abbreviated
				application.</text>
							</paragraph>
            </subsection>
          </section>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</section>
      <section commented="no" display-inline="no-display-inline" id="id86BF1F833AFE43B28EDEE90F35A3DA96" section-type="subsequent-section">
        <enum>203.</enum>
        <header display-inline="yes-display-inline">Reauthorization; reporting
			 requirements</header>
        <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:742">Section
			 742 of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-22">21 U.S.C. 379j–22</external-xref>)</cato:entity> is amended
			 to read as follows:</text>
				<quoted-block display-inline="no-display-inline" id="id007B6113BEBB47D8BCF3460EDCDFD939" style="OLC">
					<section commented="no" display-inline="no-display-inline" id="id64016AE763B143F8BB332EDA9D3D69A0" section-type="subsequent-section">
            <enum>742.</enum>
            <header display-inline="yes-display-inline">Reauthorization; reporting
				requirements</header>
						<subsection commented="no" display-inline="no-display-inline" id="idcc2b5fe0841b4a58a399eacfdda009d9">
              <enum>(a)</enum>
              <header display-inline="yes-display-inline">Performance reports</header>
              <text display-inline="yes-display-inline">Beginning with fiscal year 2014, not later
				than 120 days after the end of each fiscal year during which fees are collected
				under this part, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall prepare and submit to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="SSHR00">Committee on
				Health, Education, Labor, and Pensions of the Senate</cato:entity-ref>, and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="HIF00">Committee on
				Energy and Commerce of the House of Representatives</cato:entity-ref> a report concerning the
				progress of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> in achieving the goals identified
				in the letters described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Animal Generic Drug User Fee Amendments of 2013/s:201/ss:b" proposed="true">section 201(b) of the Animal Generic Drug User Fee
				Amendments of 2013</cato:entity-ref> toward expediting the generic new animal drug development
				process and the review of abbreviated applications for generic new animal
				drugs, supplemental abbreviated applications for generic new animal drugs, and
				investigational submissions for generic new animal drugs during such fiscal
				year.</text>
						</subsection>
            <subsection commented="no" display-inline="no-display-inline" id="id835ab04b07944f3495a0b776958364cf">
              <enum>(b)</enum>
              <header display-inline="yes-display-inline">Fiscal report</header>
              <text display-inline="yes-display-inline">Beginning with fiscal year 2014, not later
				than 120 days after the end of each fiscal year during which fees are collected
				under this part, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall prepare and submit to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="SSHR00">Committee on Health,
				Education, Labor, and Pensions of the Senate</cato:entity-ref> and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="HIF00">Committee on Energy and
				Commerce of the House of Representatives</cato:entity-ref> a report on the implementation of the
				authority for such fees during such fiscal year and the use, by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and
				Drug Administration</cato:entity-ref>, of the fees collected during such fiscal year for which
				the report is made.</text>
						</subsection>
            <subsection commented="no" display-inline="no-display-inline" id="ide8a865f3fe1b4ddcb4bce882749273bc">
              <enum>(c)</enum>
              <header display-inline="yes-display-inline">Public availability</header>
              <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall make the reports
				required under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:742/ss:a" proposed="true">subsections (a)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:742/ss:b" proposed="true">(b)</cato:entity-ref> available to the public on the Internet
				Web site of the Food and Drug Administration.</text>
						</subsection>
            <subsection commented="no" display-inline="no-display-inline" id="idfc6a959f0e7c4f0e9ae966273a14cbfa">
              <enum>(d)</enum>
              <header display-inline="yes-display-inline">Reauthorization</header>
							<paragraph commented="no" display-inline="no-display-inline" id="idac49410f3e04466eb5d4705b029658a1">
                <enum>(1)</enum>
                <header display-inline="yes-display-inline">Consultation</header>
                <text display-inline="yes-display-inline">In
				developing recommendations to present to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref> with respect to the goals,
				and plans for meeting the goals, for the process for the review of abbreviated
				applications for generic new animal drugs for the first 5 fiscal years after
				fiscal year 2018, and for the reauthorization of this part for such fiscal
				years, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall consult with—</text>
								<subparagraph commented="no" display-inline="no-display-inline" id="id4424ac037ce048e08c13f9ace54078f0">
                  <enum>(A)</enum>
                  <text display-inline="yes-display-inline">the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="HIF00">Committee on Energy and Commerce of the
				House of Representatives</cato:entity-ref>;</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id3c0b326cc82b4f2eb486d437381d908d">
                  <enum>(B)</enum>
                  <text display-inline="yes-display-inline">the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="SSHR00">Committee on Health, Education, Labor,
				and Pensions of the Senate</cato:entity-ref>;</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id2007e9060e7f4ce0b9906b7dc174a91e">
                  <enum>(C)</enum>
                  <text display-inline="yes-display-inline">scientific and academic experts;</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="idcbae80e7d0434ac3bb6fc50b2419692b">
                  <enum>(D)</enum>
                  <text display-inline="yes-display-inline">veterinary professionals;</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id8a94fc1d5b374adaafd894f8aea8ad47">
                  <enum>(E)</enum>
                  <text display-inline="yes-display-inline">representatives of patient and consumer
				advocacy groups; and</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="ida454eb7bb12e4255b1ef5fabeb9e6b84">
                  <enum>(F)</enum>
                  <text display-inline="yes-display-inline">the regulated industry.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="id915ae04fbce44fa68d50558bc13be3a5">
                <enum>(2)</enum>
                <header display-inline="yes-display-inline">Prior public input</header>
                <text display-inline="yes-display-inline">Prior to beginning negotiations with the
				regulated industry on the reauthorization of this part, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				shall—</text>
								<subparagraph commented="no" display-inline="no-display-inline" id="iddd34e804fc044010a55d22cf279343bb">
                  <enum>(A)</enum>
                  <text display-inline="yes-display-inline">publish a notice in the Federal Register
				requesting public input on the reauthorization;</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="idbdd37c4c28c545cc92470a1b8f5b60ac">
                  <enum>(B)</enum>
                  <text display-inline="yes-display-inline">hold a public meeting at which the public
				may present its views on the reauthorization, including specific suggestions
				for changes to the goals referred to in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:742/ss:a" proposed="true">subsection (a)</cato:entity-ref>;</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id8023f630ea3b43e5b7f94f0391a2c307">
                  <enum>(C)</enum>
                  <text display-inline="yes-display-inline">provide a period of 30 days after the
				public meeting to obtain written comments from the public suggesting changes to
				this part; and</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id63c29888c82f4caca110a4dc9f89ad35">
                  <enum>(D)</enum>
                  <text display-inline="yes-display-inline">publish the comments on the Food and Drug
				Administration’s Internet Web site.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="idd320528a5f7645c38d661673a6a963e9">
                <enum>(3)</enum>
                <header display-inline="yes-display-inline">Periodic consultation</header>
                <text display-inline="yes-display-inline">Not less frequently than once every 4
				months during negotiations with the regulated industry, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
				hold discussions with representatives of veterinary, patient, and consumer
				advocacy groups to continue discussions of their views on the reauthorization
				and their suggestions for changes to this part as expressed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:742/ss:d/p:2" proposed="true">paragraph
				(2)</cato:entity-ref>.</text>
							</paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="idb6e5f2fa49e94ca7bcaf49911e87812b">
                <enum>(4)</enum>
                <header display-inline="yes-display-inline">Public review of
				recommendations</header>
                <text display-inline="yes-display-inline">After
				negotiations with the regulated industry, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall—</text>
								<subparagraph commented="no" display-inline="no-display-inline" id="id3e2b89a584794471bca05fa2ffd5c086">
                  <enum>(A)</enum>
                  <text display-inline="yes-display-inline">present the recommendations developed under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:742/ss:d/p:1" proposed="true">paragraph (1)</cato:entity-ref> to the congressional committees specified in such
				paragraph;</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="ida0a1729c8cc34b9dae0c2eaf1094eb5f">
                  <enum>(B)</enum>
                  <text display-inline="yes-display-inline">publish such recommendations in the Federal
				Register;</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id8cc0c572ab4d40babe8735eb35f0d0f8">
                  <enum>(C)</enum>
                  <text display-inline="yes-display-inline">provide for a period of 30 days for the
				public to provide written comments on such recommendations;</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="id94f16dea6f284626a20cfc70792d3aa4">
                  <enum>(D)</enum>
                  <text display-inline="yes-display-inline">hold a meeting at which the public may
				present its views on such recommendations; and</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="ida0afecd1e23a4b2492d2c63e3af311e0">
                  <enum>(E)</enum>
                  <text display-inline="yes-display-inline">after consideration of such public views
				and comments, revise such recommendations as necessary.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="ide67e693bd59046f0bba725622f01a5e0">
                <enum>(5)</enum>
                <header display-inline="yes-display-inline">Transmittal of
				recommendations</header>
                <text display-inline="yes-display-inline">Not later
				than January 15, 2018, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall transmit to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref> the revised
				recommendations under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:742/ss:d/p:4" proposed="true">paragraph (4)</cato:entity-ref>, a summary of the views and comments
				received under such paragraph, and any changes made to the recommendations in
				response to such views and comments.</text>
							</paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="idb6c9d4b8ddaf488fbdc61d48bc0fc4f0">
                <enum>(6)</enum>
                <header display-inline="yes-display-inline">Minutes of negotiation meetings</header>
								<subparagraph commented="no" display-inline="no-display-inline" id="id8da31d49fa5d4e03acf0fc6e923ea800">
                  <enum>(A)</enum>
                  <header display-inline="yes-display-inline">Public availability</header>
                  <text display-inline="yes-display-inline">Before presenting the recommendations
				developed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:742/ss:d/p:1..5" proposed="true">paragraphs (1) through (5)</cato:entity-ref> to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
				make publicly available, on the Internet Web site of the Food and Drug
				Administration, minutes of all negotiation meetings conducted under this
				subsection between the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> and the regulated
				industry.</text>
								</subparagraph>
                <subparagraph commented="no" display-inline="no-display-inline" id="ide3d516771ddb4edb9694aa02f70d8dfd">
                  <enum>(B)</enum>
                  <header display-inline="yes-display-inline">Content</header>
                  <text display-inline="yes-display-inline">The minutes described under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:742/ss:d/p:6/sp:A" proposed="true">subparagraph
				(A)</cato:entity-ref> shall summarize any substantive proposal made by any party to the
				negotiations as well as significant controversies or differences of opinion
				during the negotiations and their
				resolution.</text>
								</subparagraph>
              </paragraph>
            </subsection>
          </section>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</section>
      <section commented="no" display-inline="no-display-inline" id="idE3F39FD53D1C45CCAF4D42AE9FAB3054" section-type="subsequent-section">
        <enum>204.</enum>
        <header display-inline="yes-display-inline">Savings
			 clause</header>
        <text display-inline="no-display-inline">Notwithstanding the
			 amendments made by this title, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/ch:VII/sch:C/pt:5">part 5 of subchapter C of chapter VII of the
			 Federal Food, Drug, and Cosmetic Act</cato:entity-ref>, as in effect on the day before the date
			 of enactment of this title, shall continue to be in effect with respect to
			 abbreviated applications for a generic new animal drug and supplemental
			 abbreviated applications for a generic new animal drug (as defined in such part
			 as of such day) that on or after October 1, 2008, but before October 1, 2013,
			 were accepted by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> for filing with respect to
			 assessing and collecting any fee required by such part for a fiscal year prior
			 to fiscal year 2014.</text>
			</section>
      <section commented="no" display-inline="no-display-inline" id="id0093861360504679B096AF5D36435FAA" section-type="subsequent-section">
        <enum>205.</enum>
        <header display-inline="yes-display-inline">Effective
			 date</header>
        <text display-inline="no-display-inline">The amendments made by
			 this title shall take effect on October 1, 2013, or the date of enactment of
			 this Act, whichever is later, except that fees under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/ch:VII/sch:C/pt:5">part 5 of subchapter C of
			 chapter VII of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref>, as amended by this
			 title, shall be assessed for all abbreviated applications for a generic new
			 animal drug and supplemental abbreviated applications for a generic new animal
			 drug received on or after October 1, 2013, regardless of the date of enactment
			 of this Act.</text>
			</section>
      <section commented="no" display-inline="no-display-inline" id="id6738992BAF6E4409B631A215FF4D8E5C" section-type="subsequent-section">
        <enum>206.</enum>
        <header display-inline="yes-display-inline">Sunset dates</header>
				<subsection commented="no" display-inline="no-display-inline" id="id7d12783b3b50456b9bcaeb4239a18160">
          <enum>(a)</enum>
          <header display-inline="yes-display-inline">Authorization</header>
          <text display-inline="yes-display-inline">
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741" proposed="true">Section
			 741 of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-21">
                <cato:entity-ref entity-type="uscode" value="usc/21/379j–21" proposed="true">21 U.S.C. 379j–21</cato:entity-ref>
              </external-xref>)</cato:entity> shall cease
			 to be effective October 1, 2018.</text>
				</subsection>
        <subsection commented="no" display-inline="no-display-inline" id="ide4387464b55c450689665d11bd28c6a9">
          <enum>(b)</enum>
          <header display-inline="yes-display-inline">Reporting requirements</header>
          <text display-inline="yes-display-inline">
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:742" proposed="true">Section 742 of the Federal Food, Drug, and Cosmetic
			 Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-22">
                <cato:entity-ref entity-type="uscode" value="usc/21/379j–22" proposed="true">21 U.S.C. 379j–22</cato:entity-ref>
              </external-xref>)</cato:entity> shall cease to be effective January 31, 2019.</text>
				</subsection>
        <subsection commented="no" display-inline="no-display-inline" id="id118d05bc7b3c4d39aef1e2668cd6cbbc">
          <enum>(c)</enum>
          <header display-inline="yes-display-inline">Previous sunset provision</header>
					<paragraph commented="no" display-inline="no-display-inline" id="id560945a3ba304afcbfb7e9fb3fe3f851">
            <enum>(1)</enum>
            <header display-inline="yes-display-inline">In general</header>
            <text display-inline="yes-display-inline">
            <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Animal Generic Drug User Fee Act of 2008/s:204">Section 204 of the Animal Generic Drug User Fee Act of
			 2008</cato:entity-ref> (<external-xref legal-doc="public-law" parsable-cite="pl/110/316">Public Law 110–316</external-xref>)</cato:entity> is repealed.</text>
					</paragraph>
          <paragraph commented="no" display-inline="no-display-inline" id="idb437a3f3cd77458aaa8b9fdd29c5c6a7">
            <enum>(2)</enum>
            <header display-inline="yes-display-inline">Conforming amendment</header>
            <text display-inline="yes-display-inline">The <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Animal Generic Drug User Fee Act of 2008">Animal Generic Drug User Fee Act of 2008</cato:entity-ref> (<cato:entity-ref entity-type="public-law" value="public-law/110/316">Public
			 Law 110–316</cato:entity-ref>)</cato:entity> is amended in the table of contents in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Animal Generic Drug User Fee Act of 2008/s:1">section 1</cato:entity-ref>, by striking the
			 item relating to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Animal Generic Drug User Fee Act of 2008/s:204">section 204</cato:entity-ref>.</text>
					</paragraph>
        </subsection>
      </section>
    </title>
  </legis-body>
	<attestation>
		<attestation-group>
			<attestation-date chamber="Senate" date="20130508">Passed the Senate
			 May 8, 2013.</attestation-date>
			<attestor display="no"/>
			<role>Secretary</role>
		</attestation-group>
	</attestation>
	<endorsement display="yes">
	</endorsement>
</bill>
</doc>